Any and all information presented in this document shall be treated as confidential and shall remain the exclusive property o f [COMPANY_011] (or any of its 
affiliated companies). The use of such confidential information must be restricted to the recipi[INVESTIGATOR_109685] t for the agreed purpose and must not be 
disclosed, published or otherwise communicated to any unauthorized persons, for any reason, in any form whatsoever without th e prior written 
consent of [COMPANY_011] (or the concerned affiliated company); ‘affiliated compa ny’ means any corporation, partnership or other entity which at the date 
of communication or afterwards (i) controls directly or indirectly [COMPANY_011], (ii) is directly or indirectly controlled by [CONTACT_13095] i, with ‘control’ meaning 
direct or indirect ownership of more than 50% of the capi[INVESTIGATOR_13040], partnership or other entity
According to template: RDSD -002540 VERSION N° 2 .0 (11-OCT -2018) based on TransCelerate CPT version 5 Page 1CLINICA L TRI AL PROTO COL
Protocol title: A Randomized, Double -blind, Placebo -controlled, 
Parallel -group, 52 -week Pi[INVESTIGATOR_714294] , Safety , and Tolerability  of Dupi[INVESTIGATOR_208400] -to-severe Chron ic Obstructive 
Pulmonary  Disease (COPD) w ith Type 2 inflammation
Protocol number: EFC15804 (BOREA S)
Amendment number: Not applicable
Compound number 
(INN/Trademark ):SAR231893/REGN668 (dupi[INVESTIGATOR_12458])
Study p hase: Phase 3
Short title: Pi[INVESTIGATOR_714295] , safety and 
tolerability  of dupi[INVESTIGATOR_208402] -to-
severe COPD with Type 2 inflammation (BOREA S)
Sponsor name:   
[CONTACT_245668] :  
Monitoring Team’s 
Represen tative Name 
[CONTACT_9352] [CONTACT_714374](s):
IND: [ADDRESS_972795] : 2018- [ADDRESS_972796]: Not yet available
WHO: U1111 -1211 -8804
Other: Not a pplicable
Approval Date: 07-Nov-2018 Total number o f pages: 108
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Pr otocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: [ADDRESS_972797] OF FIGURES .......................................................................................................................................... 6
1 PROTOCOL SUMMA RY................................................................................................................. 7
1.1 SYNOPSIS ....................................................................................................................................... 7
1.2 SCHEMA ........................................................................................................................................ 12
1.3 SCHEDULE OF ACTIVITI ES (SOA) .............................................................................................. 13
1.3.1 Schedule of activities for patients who complete the planned treatment ....................................... 13
1.3.2 Reduced schedule of events for patients afte r early treatment discontinuation ............................ 18
2 INTRODUCTION ............................................................................................................................ 21
2.1 STUDY RATIONALE ...................................................................................................................... 21
2.2 BACKGROUND ............................................................................................................................. 21
2.2.1 Dupi[INVESTIGATOR_161376] -IL4Rα monoclonal antibody .................................................................................. 23
2.3 BENEFIT/RISK ASSESSM ENT ..................................................................................................... [ADDRESS_972798] UDY DEFINITION ....................................................................................................... 29
5 STUDY POPUL ATION.................................................................................................................. 30
5.1 INCLUSION CRITERIA .................................................................................................................. 30
5.2 EXCLUSION CRITERIA ................................................................................................................. 31
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Pr otocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 35.3 LIFESTYLE CONSIDERAT IONS ................................................................................................... 35
5.4 SCREEN FAILURES ...................................................................................................................... 35
6 STUDY INTERVENTION ............................................................................................................... 36
6.1 STUDY INTERVENTION(S ) ADMINISTERED .............................................................................. [ADDRESS_972799](S) .......................................................................... [ADDRESS_972800](S) .................................................................. 37
6.2 PREPARATION/HANDLING /STORAGE/ACCOUNTABIL ITY....................................................... 39
6.3 MEASURES TO MINIMIZE BIAS: RANDOMIZATION AND BLINDING ....................................... 40
6.3.1 Methods of assigning patients to treatment group ......................................................................... 40
6.3.2 Methods of blinding ........................................................................................................................ 41
6.3.3 Randomization code breaking during the study ............................................................................. 41
6.4 STUDY INT ERVENTION COMPLIANCE ...................................................................................... 42
6.5 CONCOMITANT THERAPY .......................................................................................................... 42
6.6 DOSE MODIFICATION .................................................................................................................. 43
6.7 INTERVENTION AFTER T HE END OF THE STUDY ................................................................... 43
7 DISCONTINUA TION OF STUDY INTERV ENTION A ND PA RTICIPA NT 
DISCONTINUA TION/WITH DRA WAL........................................................................................... 44
7.1 DISCONTINUATION OF STUDY INTERVENTION ...................................................................... 44
7.1.1 Permanent discontinuation ............................................................................................................ 44
7.2 PARTICIPA NT DISCONTINUATION/ WITHDRA WAL FROM THE S TUDY .................................. [ADDRESS_972801] TO FOLLOW  UP.................................................................................................................. 47
8 STUDY A SSESSMENTS AN D PROCEDURES ........................................................................... 48
8.1 EFFICACY ASSESSMENTS ......................................................................................................... 48
8.1.1 Disease -specific efficacy measures ............................................................................................... 48
8.1.2 Clinical outcome assessments ....................................................................................................... 50
8.2 SAFETY ASSESSMENTS ............................................................................................................. 52
8.2.1 Physical examinations .................................................................................................................... 52
8.2.2 Vital signs ....................................................................................................................................... 53
8.2.3 Electrocardiograms ........................................................................................................................ 53
8.2.4 Clinical safety laborator y assessments .......................................................................................... 53
8.3 ADVERSE EVENTS AND S ERIOUS ADVERSE EVENT S........................................................... 54
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Pr otocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: [ADDRESS_972802] ................................................................................................... 54
8.3.2 Time period and frequency for collecting AE and SAE information ............................................... 56
8.3.3 Method of detecting AEs and SAEs ............................................................................................... 56
8.3.4 Follow -up of AEs and SAEs ........................................................................................................... 56
8.3.5 Regulatory reporting requirements for SAEs ................................................................................. 56
8.3.6 Pregnancy ...................................................................................................................................... 57
8.3.7 Adjudication Committee ................................................................................................................. 57
8.3.8 Disease -related events and/or disease -related outcomes not qualifying as AEs or SAEs ........... [ADDRESS_972803] complaints / medical device incidents (including 
malfunctions) .................................................................................................................................. 57
8.4 TREATMENT OF OVERDOS E...................................................................................................... 57
8.5 PHARMACOKINETICS .................................................................................................................. 58
8.5.1 Systemic drug concentration and anti -drug antibodies .................................................................. 58
8.6 PHARMACODYNAMICS ............................................................................................................... 59
8.6.1 Pharmacodynamic variables/biomarkers ....................................................................................... 59
8.7 PHARMACOGENOMICS ............................................................................................................... 60
8.8 BIOMARKERS ............................................................................................................................... 61
8.9 HEALTH CARE RESOURCE UTILIZATION ................................................................................. 61
9 STATISTICA L CONSIDER ATIONS .............................................................................................. 62
9.1 STATISTICAL HYPOTHES ES....................................................................................................... 62
9.2 SAMPLE SIZE DETERMIN ATION ................................................................................................ .62
9.3 POPULATIONS FOR ANAL YSES ................................................................................................ .63
9.4 STATISTICAL ANALYSES ............................................................................................................ 64
9.4.1 Efficacy  analyses ........................................................................................................................... 64
9.4.2 Safety analy ses.............................................................................................................................. 66
9.4.3 Other analy ses............................................................................................................................... 67
9.5 INTERIM ANALYSES .................................................................................................................... 68
10 SUPPORTING DOCUMENT ATION A ND OPERA TIONA LCONSIDERA TIONS ........................ 69
10.1 APPENDIX 1: REGULATO RY, ETHICAL, AND STU DY OVERSIGHT CONSIDE RATIONS .......69
10.1.1 Regulatory and Ethical Considerations .......................................................................................... 69
10.1.2 Informed consent process .............................................................................................................. 69
10.1.3 Data protection ............................................................................................................................... 70
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Pr otocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 510.1.4 Committees structure ..................................................................................................................... 70
10.1.5 Dissemination of clinical study  data ............................................................................................... 71
10.1.6 Data quality assurance ................................................................................................................... 71
10.1.7 Source documents ......................................................................................................................... 72
10.1.8 Study and site closure .................................................................................................................... 72
10.1.9 Publication policy ........................................................................................................................... 72
10.2 APPENDIX 2: CLINICAL LABORATORY TESTS ......................................................................... 73
10.3 APPENDIX 3: ADVERSE EVENTS: DEFINITIONS AND PROCEDURES FOR 
RECORDING, EVALUATIN G, FOLLOW -UP, AND REPORTING ................................................. 74
10.4 APPENDIX 4: CONTRACE PTIVE GUIDANCE AND C OLLECTION OF PREGNAN CY 
INFORMATION .............................................................................................................................. 79
10.5 APPENDIX 5: GENETICS .............................................................................................................. 81
10.6 APPENDIX 6: LIVER AND OTHER SAFETY: SUGG ESTED ACTIONS AND  F OLLOW -UP 
ASSESSMENTS ............................................................................................................................ 82
10.7 APPENDIX 7: LIST OF PROHIBITED LIVE ATTE NUATED VACCINES ...................................... 83
10.8 APPENDIX 8: COUNTRY -SPECIFIC REQUIREMENT S.............................................................. 84
10.9 APPENDIX 9: ABBREVIA TIONS ................................................................................................... 84
10.10 APPENDIX 10: ST. GEO RGE’S RESPI[INVESTIGATOR_714296] .......................................... 86
10.11 APPENDIX 11: THE EXA CT AS FORMATTED FOR PERSONAL DIGITAL ASS ISTANT 
(PDA) .............................................................................................................................................. 92
10.12 APPENDIX 12: EXACT Q UESTIONNAIRE ................................................................................... 94
10.13 APPENDIX 13: BODE .................................................................................................................. 100
10.14 APPENDIX 14:  EQ -5D................................................................................................................ 101
10.15 APPENDIX 15: DEFINIT ION OF ANAPHYLAXIS ....................................................................... 104
10.16 APPENDIX 16: LIST OF OPPORTUNISTIC INFECTI ONS ......................................................... 104
10.17 APPENDIX 17: FUTURE USE OF SAMPLES ............................................................................. 105
11 REFERENCES ............................................................................................................................. 106
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Pr otocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: [ADDRESS_972804] OF TA BLES
Table 1 -Objectives and endpoints ............................................................................................................... 25
Table 2 -Overview of study interventions administered ............................................................................... 36
Table 3 -Reliever medication - Salbutamol/Albuterol nebulizer solution ...................................................... 38
Table 4 -Reliever medication - Levosalbutamol/Levalbuterol nebulizer solution ......................................... 38
Table 5 -Reliever medication - L pratropi[INVESTIGATOR_208405]/short -acting β agonists [SABA] nebulizer 
solutions ......................................................................................................................................................... [ADDRESS_972805] OF FIGURES
Figure 1 -Graphical study design ................................................................................................................. 12
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Pr otocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 71 PROTOCOL SUMMA RY
1.1 SYNOPSIS
Protocol title: A Randomized, Double -blind, Placebo -controlled, Parallel- group, 52 - week 
Pi[INVESTIGATOR_714297] , Safet y, and Tolerability of Dupi[INVESTIGATOR_714298] -to-severe Chronic Obstructive Pulmonary  Disease 
(COPD) with Ty pe 2 inflammation
Short title: Pi[INVESTIGATOR_714295] , safet y and tolerability  of dupi[INVESTIGATOR_714299] -to-severe COPD with Ty pe 2 inflammation
Rationale:
Chronic obstructive pulmonary  disease (COPD) is a highl y prevalent disease worldwide, 
associated with significant economic burden, and for which available standard -of-care therap y 
shows insufficient treatment effect on s ymptoms, lung function, exacerbations and long term 
evolution of the disease. Though the inflammatory  component in COPD is ty pi[INVESTIGATOR_1306] y thought to be 
neutrophils, there has been an identified subgroup of COPD which is characterized with a 
concomitant elevation in bl ood eosinophils which suggests a Ty pe [ADDRESS_972806] on lung function and sy mptom control will be 
evaluated over both the short and long term.
Objectives and endpoints
Objective s Endpoint s
Primary
To evaluate the efficacy of dupi[INVESTIGATOR_12458] 300 mg q2w in patients 
with moderate or severe COPD as measured by
 Annual ized rate of acute moderate or severe COPD 
exacerbation (AECOPD)
 Pre-bronchodilator forced expi[INVESTIGATOR_3741] 1 
second (FEV 1) over 12 weeks compared to placebo Annualized rate of moderate* or severe** COPD 
exacerbations over the 52 -week treatment period
compared to placebo
 Change in pre -bronchodilator FEV 1from baseline to 
Week 12 compared to placebo
*Moderate exacerbations are recorded by [CONTACT_714375] (such as intramuscular, intraven ous or 
oral) and/or antibiotics. 
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Pr otocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 8**Severe exacerbations are recorded by [CONTACT_714376][INVESTIGATOR_059], 
emergency medical care visit or result in death
        For both moderate and severe events to be counted as 
separate events, they must be separated by [CONTACT_2669] [ADDRESS_972807] of  dupi[INVESTIGATOR_12458] 300 mg q2w on
Health related quality of life, assessed by [CONTACT_555847] [ADDRESS_972808]. George’s Respi[INVESTIGATOR_6004] (SGRQ) 
Pre-bronchodilator FEV 1over 52 weeks compared to 
placeboChange from baseline to Week 52 in SGRQ total score 
compared to placebo
Proportion of patients with SGRQ improvement ≥4 points at 
Week 52
Change in pre -bronchodilator FEV 1from baseline to 
Week 52 co mpared to placebo
Overall design:
Multinational, randomized, double- blind, placebo -controlled, parallel group (2 groups), 52-week, 
pi[INVESTIGATOR_9205] [ADDRESS_972809] (LABA ), long acting muscarinic 
antagonist (LAMA ) and/or inhaled corticosteroid (I CS)background therapy  (triple therapy  unless 
ICS contraindicated ). Study  treatments are dupi[INVESTIGATOR_12458] 300 mg q2w or placebo q2w administered 
during the 52 -week randomized treatment period. The study  includes 3 study  periods
Screening (4 weeks ±1 week)
Randomized investigational medicinal product (I MP) treatment period (52 weeks± 3 day s)
Post I MP treatment period (12 weeks ±5 day s) 
Patients who satisfy  the inclusion and exclusion criteria will be randomized (1:1) to one of the 
following IMP treatment groups to be administered for 52 weeks
Dupi[INVESTIGATOR_12458] 300 mg, administered as 1 subcutaneous (SC) injection q2w 
Placebo, administered as 1 SC injection of placebo matching dupi[INVESTIGATOR_714300] b y countr y and by  [CONTACT_714377] e (yes or no) at baseline.
Treatment discontinuation follow -up:
Patients who discontinue the study  treatment prematurel y (prior to completing the 52 -
week 
treatment period) will perform, as soon as possible, the early  treatment discontinuation (ETD ) 
visit with all assessments normally  planned for the end of treatment (EOT) visit, to assure a 
complete clinical assessment in close temporal proximity  to the premature termination of study  
treatme nt is available. In addition, to allow assessment of patient outcomes over the stipulated 
study  period, patients will be asked and encouraged to complete all remaining study  visits, and 
participate in all safet y follow -up assessments according to the visit schedule. For these patients 
the assessment schedule will be reduced ( seeSection 1.3.2) and visits during the planned 
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Pr otocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 9treatment period may  be conducted by  [CONTACT_648] (except for pl anned EOT) if patient is unable to 
come in for a site visit. Assessments not completed via phone should be performed at the next 
scheduled visit. For further details please see Section 7.1.1.
Post-IMP treatment follow -up
Upon completing the 52 -weeks randomized I MP treatment period, patients will continue their
background ICS/LABA/LAMA therap y and enter the [ADDRESS_972810] -treatment period (see Section 6.1.2 for further details ).
Disclosure Statement: 
This is a Parallel Treatment study  with 2 arms that is blinded for patient s
andtheInvestigator .
Number of participants:
Approximately  924 patients are planned to be randomly  assigned to study  intervention for an 
estimated total of 462evaluable patients
per intervention group (see Section 9.2).
Intervention groups and 
duration :
Study  participation for each patient will be a total of approximately  69 weeks including up to 5 
weeks for screening, 52 weeks of IMP treatment period and 12 weeks of follow -up.
Study interve ntion(s)
Investigational medicinal products
Dupi[INVESTIGATOR_12458] 300 mg
Formulation: Dupi[INVESTIGATOR_12458] 300 mg for SC administration is supplied as 150 mg/mL  solution 
in 2.25 mL  prefilled glass sy ringes to deliver 300 mg in 2 mL .  
Route of administration: subcutaneous inject ion. All I MP applications will be done as 
separate injections into different injection sites
Dose regimen: dupi[INVESTIGATOR_12458] 300 mg q2w administered as 1 SC injection 
Matching Placebo for dupi[INVESTIGATOR_12458]
Formulation: Placebo matching dupi[INVESTIGATOR_714301]. 
Route of administration: subcutaneous injection. All I MP applications will be done as 
separate injections into different injection sites
Dose regimen: Placebo administered as 1 SC injection of placebo matching dupi[INVESTIGATOR_12458] 
300mg (2 mL)
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Pr otocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 10Noninvestigational medicinal products(s)
Background therapy
Patients should continue the regular administration of their previous standard o fcare backgr ound 
therap y for COPD throughout the study , including :
Triple therap y: ICS + LABA + LAMA (Double therap y: LABA + LAMA allowed if I CS is 
contraindicated)
Formulation: dry  powder inhaler (DPI ), metered dose inhaler (MDI ) or pocket nebulizer
Route(s) of administration: Oral inhalation
Dose regimen: As prescribed
Background medication should not be adjusted during Screening. Patients are strongl y encouraged 
to maintain their background therap y for the entir e duration of their treatment therapy . After 1 
severe or 2 moderate exacerbations of COPD, dose adjustments in background therapy , if required 
will be permitted for s ymptom control and as needed for the remainder of the trial period. 
Reliever medication
Patients may  use albuterol/salbutamol or levalbuterol/levosalbutamol (including ipratropi[INVESTIGATOR_208454]/short acting β -agonist [SABA] combinations or terbutaline ) as reliever medications as 
needed during the stud y. 
Formulation: MDI, nebulizer solutions or DPI
[INVESTIGATOR_714302]: oral inhalation
Dose regimen: as prescribed
Statistical considerations:
Analy sis populations
-The efficacy  population will be the intention- to-treat (ITT ) population, defined as all 
randomized patients analy zed according to the treatment group allocated by  
[CONTACT_17628].
-The safet y population will include all patients who actuall y received at least one dose 
or partial of a dose of the I MP, analy zed according to the treatment a ctually  received.
Primary analysis: The annualized rate of moderate or severe COPD exacerbation events 
will be anal yzed using a negative binomial regression model. The model will include the 
total number of events occurring during the 52 -week treatment per iod as the response 
variable, with the treatment group, region (pooled country ), asthma history  (Yes or No), 
smoking status at screening (current smokers or not), baseline disease severity  (as % 
predicted post -bronchodilator FEV 1), and number of moderate o r severe COPD 
exacerbation events within one y ear prior to the study  (≤2, 3, or ≥4) as covariates. Log -
transformed observation duration will be used as offset variable. Patients who permanently  
discontinue the study  treatment will be encouraged to complete the study  as planned and 
the additional off -treatment exacerbation events up to Week 52 will be included in the 
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Pr otocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: [ADDRESS_972811] model with repeated measures (MMRM ). The model will include change 
from baseline in FEV 1values up to Week 12 as response variables, and factors for 
treatment group, age, sex, baseline height, region (pooled country ), asthma history  (Yes or 
No), smoking status at screening (current smokers or not), visit, treatment -by-visit 
interaction, baseline pre -bronchodilator FEV 1, and FEV 1baseline -by-visit interaction as 
covariates. An unstructured correlation matrix will be used to model the within -patient 
errors. Parameters will be estimated using restricted maximum likelihood method u sing 
the Newton- Raphson algorithm. For patients discontinued the study  treatment, off-
treatment FEV 1values will be included in the analy sis. Sensitivity  anal yses for handling 
missing data may  include pattern mixture model by  [CONTACT_714378] g point 
analyses.
Analysis of key secondary endpoints: The change from baseline in pre -bronchodilator 
FEV 1at Week [ADDRESS_972812] except that the MMRM model will include the following covariat es: treatment group, 
region (pooled country ), asthma history  (Yes or No), smoking status at screening (current 
smokers or not), visit, treatment -by-visit interaction, baseline SGRQ total score, and 
SGRQ baseline- by-visit interaction. 
The proportion of patients with SGRQ improvement ≥4 points at Week 52 will be 
analyzed using a logistic regression model. The model will include treatment group, region 
(pooled country ), asthma history  (Yes or No), smoking status at screening (current 
smokers or not), and base line SGRQ total score as covariates. Patients with missing SGRQ 
total score at Week 52 will be considered as non -responders .
Multiplicity considerations: Multiplicity  is considered for testing multiple endpoints. The 
overall ty pe-I error rate will be contr olled at the two -sided 0.05 level. Details will be 
provided in Section [IP_ADDRESS].
Safety analyses: The safety  variables, including adverse events (AEs) , laboratory  
parameters, vital signs, electr ocardiograph y, and phy sical examinations will be 
summarized using descriptive statistics.
Interim analysis :An interim anal ysis (IA) in the study  is planned to be performed when 
approximately  [ADDRESS_972813] completed Week 12 visit. Further details are 
provided in Section
9.5.
Data Monitoring Committee: Yes
A data monitoring committee (DMC ), independent from S ponsor, will be es
tablished for this 
study . This committee is comprised of externall y-based individuals with expertise in the diseases 
under study, biostatistics, or clinical research. The primary  responsibilities of the DMC are to 
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Pr otocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: [ADDRESS_972814] of the clinical trial to the Sponsor.
1.2 SCHEMA
Figure 1 -Graphical study design
(electronic  
  
1.0)VV-CLIN-0646876 1.0
VV-CLIN-0646876 1.0
VV-CLIN-0646876 1.0
VV-CLIN-0646876 1.0
Clinical Trial Pr otocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 16β-hCG = Human chorionic gonadotropin-beta; BID = twice daily assessments; continuous = subsequent visits during the treatment period; COPD = chronic obstructive p ulmonary disease; cont. = 
continuous; DNA = Deoxyribonucleic acid ; EDTA = Ethylenediaminetetr aacetic acid ; EOS = End of Study; EOT = End of treatment; EQ- 5D= Euro Quality of Life -5 Dimension questionnaire; EXACT 
= Exacerbations of COPD tool; FeNO = Fractional exhaled nitric oxide; HIV = human immunodeficiency virus; IgE = Immunoglobuli n E; IMP = Investigational Medicinal Product; IVRS = Interactive 
Voice Response System; IWRS = Interactive Web Response System; LABA = Long -acting β2 agonists; LAMA = Long -acting muscarinic antagonist ; PARC = Pulmonary and activation- regulated 
chemokine; PGX = pharm acogenetic; PK = Pharmacokinetic; RNA = Ribonucleic acid; SABA = Short -acting β-agonists; SAEs = Serious adverse events; SC = subcutaneous; SGRQ = St. George's 
Respi[INVESTIGATOR_6015].
aRandomization/baseline Visit is defined as Day 1. The visit schedule should be adhered to within ±1 week for the screening period, ±3 days for the randomized IMP treatment period and ±[ADDRESS_972815] IMP treatment period.
bAll assessments at Visit 2 (Day 1) are to be conducted pre -IMP dose with the exception of the assessment of local tolerability of SC injections.
cEnd-of-treatment visit: See Section 7.1.1 for patients who discontinue treatment prematurely.
dECG to be centrally collected & read.  
eChest X -ray to be performed unless a <[ADDRESS_972816] x- ray/chest CT/chest MR is available. In case chest -X-ray is not feasible due to local regulations, magnetic resonance imaging (MRI) 
will be performed. 
fIMP (Dupi[INVESTIGATOR_24885]) is to be administered every 2 wee ks by [CONTACT_4676], caregiver or healthcare professional at the patient’s home or in a health care facility.  Last dose will be gi ven at Week 
50. After Week 8, if the patient or Investigator decides not to administer IMP at home, the IMP injections can be perfo rmed at the site by [CONTACT_181252]. Patients will be monitored at 
the study site for a minimum of 30 minutes after injections. See Section 6.1.1 for details.
gElectron ic diary is used for recording of patient’s answers to the EQ- 5D-5L, EXACT and SGRQ questionnaires. This handheld device is dispensed at Screening Visit 1 (including instructions for 
use) and recorded information is reviewed on the other indicated days. At EOT visit the electronic diary is downloaded from the device and returned to the site.
hComplete physical examinations will include skin, nasal cavities, eyes, ears, respi[INVESTIGATOR_696], cardiovascular, gastrointestinal, neurological, lymphatic, and musculoskeleta l systems.
iVital signs, including systolic and diastolic blood pressure (mmHg), pulse rate (beats per minute), body temperature (°C), an d respi[INVESTIGATOR_148235], baseline and every 
subsequent on -site visit. Height (cm) will be measu red at screening (Visit 1) only. Body weight (kg) will be measured at screening (Visit 1) and at EOT/EOS visits.
jHematology will include hemoglobin, hematocrit, platelet count, total white blood cell count, differential count, and total r ed blood cell count. Serum chemistry will include include creatinine, blood 
urea nitrogen, glucose, lactate dehydrogenase, uric acid, total cholesterol, total protein, albumin, total bilirubin, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, 
electrolytes (sodium, potassium, chloride), bicarbonate, and creatine phosphokinase. Urinalysis will include specific gravity, pH , glucose, ketones, blood, protein, nitrate, leukocyte esterase, 
urobilinogen and bilirubin. If any parameter on the dipstick is ab normal, a urine sample should be sent to the central laboratory for quantitative measurement. If positive for protein and/or red 
blood cells, microscopic analysis will be performed by [CONTACT_2237]. 
Clinical laboratory testing at Screening Visit 1 will include hepatitis screen covering hepatitis B surface antigen (HBs Ag), hepatitis B surface antibody (HBs Ab), hepatit is B core antibody (HBc 
Ab), hepatitis C virus antibodies (HCV Ab), Human Immunodeficiency Virus (HIV) screen (Anti -HIV-1 and HIV -2antibodies) and anti -nuclear antibody (ANA). In case of results showing HBs Ag 
(negative), and HBc Ab (positive), an HBV DNA testing will be performed prior to randomization to rule out a false positivity if the Investigator believes the patient is a fals e positive, or to clarify 
the serological status if the Investigator finds it unclear to interpret in absence of known HBV infection. In case of result s showing HCV Ab (positive), an HCV RNA testing may be performed to 
rule out a false positivity, if the I nvestigator believes t he patient is a false positive. Note: Anti- ds DNA antibody will be tested if ANA is positive (≥1:160 titer). 
kRefer to central lab manual for collection details.
lOnly for women of childbearing potential. Pregnancy will lead to definitive treatment discontinuation in all cases. In case of positive urinary test, a serum pregnancy test should be performed as 
soon as possible to confirm the pregnancy.
mOptional sputum sample at V isit [ADDRESS_972817] sites in 
some countries. See Section [IP_ADDRESS] for details.
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Pr otocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 17nSpi[INVESTIGATOR_208413] (ERS)/American Thoracic Society (ATS) [ADDRESS_972818] dos e of salb utamol/albuterol or levosalbutamol/levalbuterol for at least [ADDRESS_972819] 12 hours (ultra -
long acting LABA like vilanterol should be withheld for at l east 24 
hours) and withholding the last dose of LAMA for at least 24 hours. This will be verified before performing the measurements. Note: When both pre and post -bronchodilator spi[INVESTIGATOR_714303], the post -bronchodilator spi[INVESTIGATOR_714304] (ie, 30 minutes for albuterol or other SABA). 
oFollowing randomization and during the treatment period -if spi[INVESTIGATOR_714305] t during the treatment period.
pPK and ADA samples to be collected prior to the administration of the drug.
qIf collection is not completed at randomization, sample can be taken at a following visit. 
rIncludes collection of sick days, lost usual activities, and additional physician visits or other health care utilization.
sTo be completed prior to IMP administration
tTo be done for 2 weeks after screening, 4 weeks after randomization (i.e Week 0 to Week 4) and between Weeks 12 and 14.
(electronic  
  
1.0)VV-CLIN-0646876 1.0
VV-CLIN-0646876 1.0
VV-CLIN-0646876 1.0
Clinical Trial Pr otocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: [ADDRESS_972820] sites in some 
countries See 
Section [IP_ADDRESS] for details. .
jSpi[INVESTIGATOR_208413] (ERS)/Ameri can Thoracic Society (ATS) [ADDRESS_972821] dos e of salbutamol/albuterol or levosalbutamol/levalbuterol for at least [ADDRESS_972822] 12 hours (ultra -long acting LABA like vilanterol should be withheld for at least 24 
hours) and withh olding the last dose of LAMA for at least 24 hours. This will be verified before performing the measurements. Note: When both pre and post- bronchodilator spi[INVESTIGATOR_714303], the post -bronchodilator spi[INVESTIGATOR_714306] (ie, 30 minutes for albuterol or other SABA). 
kThe EXACT and SGRQ are to be completed in the patient’s electronic diary.
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: [ADDRESS_972823] . It is a 
fully  human monoclonal antibody  (mAB) directed against the interleukin 4 receptor alpha 
(IL-4Rα) subunit, a component of IL -4 receptors Ty pe I and T ype II, which mediate signaling b y 
IL-4 (both receptors) and by  [CONTACT_8668]-13 (Ty pe II receptor).  The IL -4R alpha receptor is present on 
multiple cell ty pes known to be involved in the type 2 inflammatory  process.  Dupi[INVESTIGATOR_208417] a potential novel treatment for COPD in those patients with evidence of t ype 2 
inflammation as identified by  [CONTACT_208519] . 
2.1 STUDY RA TIONA LE
Chronic obstructive pulmonary  disease (COPD) is a highl y prevalent disease , associated with 
significant economic burden, and for which av ailable standard -of-care therapi [INVESTIGATOR_714307] s ymptoms, lung function, exacerbations and long term progression of the 
disease.  This study  is designed to investigate the efficacy  and safet y profile of dupi[INVESTIGATOR_714308] y ear in patien ts with COPD who are in nee d ofan additional treatment added to their current 
management. The presence of a placebo arm is appropriate for the objectives of this study , since it 
will provide the most robust assessment of the efficacy  and safety  of dupi[INVESTIGATOR_12458].  All patients will 
receive standard of care background medication throughout the study . The proposed study  design 
provides the opportunity  to investigate the efficacy  of dupi[INVESTIGATOR_714309], prevention of moderate and severe exacerbations a nd sy mptom control. 
The effect on lung function and sy mptom control will be evaluated over short term and long term.
2.2 BACKGROUND
Chronic obstructive pulmonary  disease (COPD) is a common, heterogeneous disease associated 
with an abnormal inflammatory  immune response of the lung 
to noxious particles and gases ( 1). It 
results in progressive airflow obstruction that is mainly  irreversible or only  partially  reversible 
and in many  cases loss of alveolar tissue and emp
hysema. The disease t ypi[INVESTIGATOR_714310] s, where the chronic inflammation causes structural changes including narrowing of the 
small airway s, and destruction of the lung parenchyma that leads to the loss of alveolar 
attachments to the small air ways and decreases lung elastic recoil. The inflammation component 
of COPD is thought to involve many  cell t ypes including structural cells, T ly mphocy tes, 
neutrophils, macrophages, and their biological products. Though the inflammatory  component in 
COPD i s typi[INVESTIGATOR_714311], there has been an identified subgroup of COPD 
which is characterized with a concomitant elevation in blood eosinophils which suggests a Ty pe [ADDRESS_972824] (including silica) and fumes. The 
most common clinical symptoms include chronic d yspnea, cough and/or sputum production. 
COPD exacerbations are important contributors to the disease burden, particularl y in severe 
COPD. Exacerbations are often triggered b y viral and/or bacterial infections, but tend to occur 
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 22also more frequentl y in pati ents with COPD with Ty pe 2 inflammatory  signature, where they  may  
be preceded b y increases in sputum eosinophils. Exacerbations may  trigger a major inflammatory  
response followed b y tissue destruction and frequent exacerbations which are associated with 
forced expi[INVESTIGATOR_4034] 1 second (FEV 1) decline, more rapid disease progression and 
increased risk of mortality .
In particular, current smokers with COPD have an accelerated decline in lung function, which is 
heterogeneous, exhibits considerable inter -and intra -individual variabilit y and FEV 1decline can 
reach more than 100 ml/y ear in some patients with COPD. Smoking cessation attenuates the 
accelerated loss of lung function, but neither smoking cessation nor current therapi[INVESTIGATOR_45732] a 
substantial re covery  of lung function lost at the time of smoking cessation (2).
“Type 2 inflammation” exists across a spectrum of diseases.  This inflammatory  cascade is 
regulated b y T-helper t ype 2 cells and is driven b y activation of IL-4, IL -5, and IL -13 cy tokines. 
(3). Peripheral and airway  eosinophils are present in asthm atics with ty pe 2 inflammation ( 4). 
Markers of Ty pe [ADDRESS_972825] been identified in 
subgroups of patients with COPD and are linked to peripheral eosinophils (5, 6).  In addition, 
peripheral eosinophilia (>300), as a marker of t ype [ADDRESS_972826] clinical features ( 6, 7)includ ing more frequent 
respi[INVESTIGATOR_22315] (8)as well as worse overall mortality .  At the same time, this group, 
similar to asthmatics with ty pe 2 inflammation (9), also appears to be more responsive to ICS ( 6). 
Additional biomarkers for ty pe [ADDRESS_972827] been less well studied in COPD. 
Dupi[INVESTIGATOR_714312]4Ra, leading to inhibition of the type 2 cy tokines IL -4and IL-13.In 
addition, IL-13 has been shown to block mucus secretion.  We hy pothesize that blocking key  
mediators of ty pe 2 inflammation as well as reducing mucus production in COPD will lead to a 
reduction in inflammatory  exacerbations as well as an improvement in lung function. We will use 
peripheral eosinophilia to identify  COPD patients with ty pe 2 inflammation .
Chronic obstructive pulmonary  disease i s a highl y prevalent, serious and progressive disease 
resulting in significant morbidity , mortality , and economic burden (10,11). Based on the BOLD 
and other lar ge scale epi[INVESTIGATOR_9037], it is estimated that the number of COPD cases in the 
world was 384 million in 2010, with a global prevalence of 11.7% (95% confidence interval: 
8.4%
-15.0%) ( 10). In the US alo ne there are more than [ADDRESS_972828] 
common cause of death . In Europe the number of cases is estimated to be  66.4 million in 2010 
among people aged 30 years or more, with a prevalence of 13.7 % (13.5% -
13.9% ) (10).Globally  
there are around 3 million deaths attributed to COPD annually . With the increasing prevalence of 
smoking in developi[INVESTIGATOR_14696], and aging populations in high
-income countries, the prevalence
is expected to rise and the number of deaths to reach 4.5 million by  2030. Medical comorbidities 
such as cardiovascular disease, diabetes, lung cancer, skeletal muscle d ysfunction, osteoporosis, 
psychological disturbances, and metabolic s yndrome are common among COPD patients and 
occur across the spectrum of disease severity . 
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: [ADDRESS_972829] of Care for moderate COPD starts with daily  use of bronchodilators, mostly  long -
acting muscarinic antagonists (L AMA) and/or long -acting β 2-agonists (LABA). As disease 
progresses, in particular in patients with frequent exacerbations, bronchodi lators are combined 
with anti- inflammatory  drugs such as inhaled corticosteroids (ICS), and phosphodiesterase t ype 4 
(PDE- 4) inhibitors (roflumilast) ( 12, 13, 14). The major limitations of the existing agents for 
COPD include modest efficacy and for inhaled corticosteroids an increased risk of respi[INVESTIGATOR_714313], in particular at high doses of p otent molecules and in patients 
with severe COPD. While inhaled corticosteroids have a consistent effect in reducing the risk of 
moderate COPD exacerbations defined b y a COPD deterioration requiring the use of s ystemic 
corticosteroids and/or antibiotics, t here is no consistent benefit on severe exacerbations requiring 
hospi[INVESTIGATOR_602]. There is increasing evidence that this treatment effect is primarily  driven b y 
patients with more that 2% blood eosinophils ( 15). 
Systemic, mostly  oral corticosteroids are largel y reserved for the treatment of exacerbations given 
their unacceptable safet y profile with heightened concerns for a COPD population. No approved 
therapeutic agent blocks the decline in FEV 1over time or 
modifies the progressive disease course 
of COPD. Thus there is a high unmet need for more effective treatment of this disease.
Currently , no targeted biological treatments addressing the immunological underpi[INVESTIGATOR_208425]. In Phase 3 trials, the anti -interleukin (IL -5)mAb mepolizumab showed a 
modest 18% -20% reduction of exacerbations in COPD patients with high blood eosinophils ( 16).
The anti -IL-[ADDRESS_972830] that the FEV 1improvement 
versus placebo averaging 150 mL  over time is mainly  driven b y the subgroup of patients with 
high blood eosinophils. In this study , no reduction of exacerbations was seen in the per -protocol 
population, and a numerical, but not statistically  significant, reduction of exacerbation was seen in 
the subgroup of patien ts with high blood eosinophils ( 17). 
Thus, significant unmet medical needs continue to exist in the growing population of patients with 
COPD. The main objective for new treatments is to further improve COPD sy mptoms, lung 
function, and prevent exacerbations, while optimizing adherence to the treatment.
2.2.[ADDRESS_972831] identified IL -4 and IL -13 variants that occur more 
frequentl y in COPD patients than in controls ( 18), and ty pe 2 gene expression score has been 
iden
tified in ~20% of COPD patie nts (19,20). It is known that dupi[INVESTIGATOR_714314]. 
Eosinophilic airway  inflammation is evident in 20% -40% of COPD patients (21,7)with increased 
levels of eosinophils in blood, sputum, and bronchial biopsies repor ted during a cute exacerbations 
(21,12). Additionally , through dupi[INVESTIGATOR_12458]’s blockade of the IL-[ADDRESS_972832], it is postulated that 
dupi[INVESTIGATOR_714315]  a unique role in treating t he mucous hy persecretion and goblet cell 
hyperplasia which is evident in chronic bronchitis subty pe of COPD.
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 24Dupi[INVESTIGATOR_714316] -4Rα subunit blocks signaling of the signature [CONTACT_714402] 2 cy tokines 
(IL-4 and IL-13) has a broader impact on t ype [ADDRESS_972833] an 
improved potential to treat aspects of COPD inflammation which are driven by  [CONTACT_24975] 2 
inflammatory  tone.
Dupi[INVESTIGATOR_714317] y approved for the treatment of atopic dermatitis and asthma and is in 
late-stage development for chronic rhinosinusitis with nasal poly posis (CRSwNP ), and 
eosinophilic esophagitis. At the time of protocol finalization, dupi[INVESTIGATOR_714318]. In asthma, it has demonstrated 
satisfactory  safet y and excellent efficacy in a broad spectrum of asthma patients, including severe 
asthma patients and previous smokers. The planned Phase 3 program including this study  will 
provide evidence on the efficacy  and safet y of dupi[INVESTIGATOR_714319] t ype 
2 inflammation as reflected by  [CONTACT_208526] ( ≥0.3 Giga/L) at screening .
2.3 BENEFIT/RISK A SSESSM ENT
Dupi[INVESTIGATOR_714320] 2 mediated immune disorders 
including atopic dermatitis, bronchial asthma, CRSwNP, and eosinophilic esophagitis. I n patients 
with moderate to severe uncontrolled asthma, dupi[INVESTIGATOR_208435] 46 to 70%, and consistently  improved lung function (FEV 1), including in 
oral corticosteroid dependent patients with severe asthma, in whom despi[INVESTIGATOR_040] a reduction in oral 
corticosteroid use, an improvement of 220 ml compared to placebo was observed.  A sub group 
analysis of “COPD -like” patients ( e.g. patients with age of onset asthma >40, prior smoking 
history , and post -bronchodilator FEV 1/forced vital capacit y [FVC ]<0.7) included in the Phase 3 
asthma study  (Study  EFC13579; QUEST) showed similar treatment effects in this subpopulation 
compared to the overall population . 
For dupi[INVESTIGATOR_12458], the safety data observed so far in completed and currentl y ongoing studies in 
atopic dermatitis, CRSwNP, and asthma pa tients (at the same or higher doses than that proposed 
for this study ) have demonstrated a satisfactory  safety  profile. Considering the high mortalit y of 
COPD patients, all deaths will be adjudicated. Considering that cardiovascular disease is a 
frequent a nd important comorbidity  of COPD, cardiac events will also be adjudicated throughout 
the study . The program will have an Adjudication Committee for the aforementioned events and a 
Data Monitoring Committee (DMC), which will review the benefit risk includin g the cardiac 
safet y on a regular basis . 
More detailed information about the known and expected benefits and risks and reasonabl y 
expected adverse events of dupi[INVESTIGATOR_714321]’s Brochure, Participant 
Information Leaflet, Package In sert, Development Safety  Update Report or Summary  of Product 
Characteristics .
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 253 OBJECTIVES A ND ENDPO INTS
Table 1 -Objectives and endpoints
Objectives Endpoints
Primary
To evaluate the efficacy of dupi[INVESTIGATOR_12458] 300 mg q2w in patients 
with moderate or severe COPD as measured by
 Annualized rate of acute moderate or severe COPD 
exacerbation (AECOPD)
 Pre-bronchodilator forced expi[INVESTIGATOR_3741] 1 
second (FEV 1) over 12 weeks compared to placebo Annualized rate of moderate* or severe** COPD
exacerbations over the 52 -week treatment period 
compared to placebo
 Change in pre -bronchodilator FEV 1from baseline to 
Week 12 compared to placebo
*Moderate exacerbations are recorded by [CONTACT_714375] (such as intramuscular, intravenous or 
oral) and/or antibiotics. 
**Severe exacerbations are recorded by [CONTACT_714376][INVESTIGATOR_059], 
emergency medical care visit or result in death
        For both mode rate and severe events to be counted as 
separate events, they must be separated by [CONTACT_2669] [ADDRESS_972834] of  dupi[INVESTIGATOR_12458] 300 mg q2w on
Health related quality of life, assessed by [CONTACT_555847] 52 in the S t. George’s Respi[INVESTIGATOR_6004] (SGRQ) 
Pre-bronchodilator FEV 1over 52 weeks compared to 
placeboChange from baseline to Week 52 in SGRQ total score 
compared to placebo
Proportion of patients with SGRQ improvement ≥4 points at 
Week 52
 Change in pre -bronchodilator FEV 1from baseline to 
Week 52 compared to placebo
Other Secondary
Evaluate the effects of dupi[INVESTIGATOR_12458] 300 mg q2w on lung function 
assessments Change in pre -bronchodilator FEV 1from baseline to 
weeks other than 12 and 52 (i.e. Weeks 2, 4, 8, 16, 20, 24, 
28, 36, 44 and 48) compared to placebo
 Change in post -bronchodilator FEV 1from baseline to 
Week 2, 4, 8, 12, 24, 36 and 52 compared to placebo
 Change in forced expi[INVESTIGATOR_10229] (FEF ) 25-75% from 
baseline to Weeks 2, 4, 8, 12,16, 24, 28, 36, 44, and [ADDRESS_972835] of dupi[INVESTIGATOR_714322] Annualized rate of severe COPD exacerbations compared 
to placebo over the 52 -week treatment period
 Time to first m oderate or severe COPD exacerbation 
compared with placebo during the 52 -week treatment 
period
Safety and Immunogenicity
 To evaluate safety and tolerability
 To evaluate dupi[INVESTIGATOR_714323] (ADA ) Adverse events (AE s)/treatment- emergent adverse events 
(TEAE s)
 Potentially clinically significant laborat ory abnormalities in 
hematology, biochemistry and urinalysis
 ADA against dupi[INVESTIGATOR_12458]
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 26Objectives Endpoints
Tertiary/exploratory
To evaluate the drug concentration of dupi[INVESTIGATOR_714324].
To explore the associa tion of biomarkers with treatment 
response Pharmacodynamic response of selected biomarkers
- Pulmonary and activation -regulated chemokine 
(PARC )
- Eotaxin -3
- Fractional exhaled ni tric oxide( FeNO; 
postbronchodilator) 
- Total IgE
 Fibrinogen
 Induced sputum for RNA expression (optional for patients 
at a subset of sites).
 Optional: Messenger ribonucleic acid (mRNA) sequ encing 
or whole transcriptome analysis from blood and sputum
 Optional: Deoxyribonucleic acid (DNA) for assessment of 
pharmacogenomic effects
Predictive effects of selected biomarkers on treatment 
response
To evaluate the effects of dupi[INVESTIGATOR_714325] h placebo on 
FEV 1 and FVC Annualized loss of lung function as assessed by a FEV 1
slope analysis
 Change from baseline in FVC ( % predicted and absolute 
values in mL) from baseline to Week 12, Week 24 and 
Week 52
To evaluate the effects of dupi[INVESTIGATOR_714326] d to placebo on 
annualized rate of moderate to severe COPD exacerbation 
utilizing the Exacerbations of Chronic Pulmonary Disease Tool 
(EXACT ) Evaluation of clinical respi [INVESTIGATOR_714327] (E -RS: 
COPD)  comprised in the EXACT tool
 Annualized rate of moderate to severe COPD 
exacerbations assessed by [CONTACT_208576] 52 week
To evaluate the effects of dupi[INVESTIGATOR_714328]Increase in number of controller medication after 
exacerbation
 Increase in patient total daily dose of controller medi cation 
after exacerbation
3.[ADDRESS_972836] for the evaluation of therap y in 
patients with COPD.
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 274 STUDY DESIGN
4.1 OVERA LL DESIGN
Multinational, randomized, double- blind, placebo -controlled, parallel groups (2 groups), 52-week 
Phase 3 study to assess the efficacy , safet y, and tolerability of dupi[INVESTIGATOR_208408] -to-severe Ty pe 2 inflammatory  COPD such as that driven by [CONTACT_208523]-4, IL -5, 
and IL -13 on an established LABA, LAMA and/or I CS background therapy (triple therapy  unless 
ICS contraindicated). Study  treatments are dupi[INVESTIGATOR_12458] 300 mg q2w or placebo q2w administered 
during the 52 -
week treatment period .  The stud y includes 3 study periods.
Screening period (4 weeks ±1 week)
Randomized investigational medicinal product (IMP) treatment period (52 weeks ±3 day s)
Post I MP treatment period (12 weeks ±5 day s)
Patients who satisfy  the inclusion and exclusion criteria will be randomized (1:1) to one of the 
following I MP treatment period groups to be administered for 52 weeks:
Dupi[INVESTIGATOR_12458] 300 mg, administered as 1 SC injection q2w 
Placebo administered as 1 SC injection of placebo matching dupi[INVESTIGATOR_12458] 300 mg 
Randomization will be stratified b y countr y and by [CONTACT_714379] (yes or no) .
Study intervention discontinuation follow -up
Patients who discontinue the study  intervention prematurel y (prior to completing the 52 -week 
treatment period) will perform, as soon as possible, the early  treatment discontinuation (ETD) 
visit wit h all assessments normally planned for the end of treatment (EOT ) visit, to assure a 
complete clinical assessment in close temporal proximity  to the premature termination of study  
treatment is available. In addition, to allow assessment of patient outcomes over the stipulated 
study  period, patients will be asked and encouraged to complete all remaining stud y visits, and 
participate in all safet y follow -
up assessments according to the visit schedule. For th ese patients 
the assessment schedule will be reduced (see Section 1.3.2) and visits during the planned 
treatment period may  be conducted by  [CONTACT_648] (except for planned EOT) if patient is unable to 
come in for a site visit. Assessments not completed via phone should be performed at the next 
scheduled visit.
Post IMP -treatment follow -up:
Upon completing the 52 -weeks randomized I MP treatment period, patients will continue their 
triple background ICS /LABA/LAMA therap y (unless I CS is contraindicated) and enter [ADDRESS_972837] -treatment period.
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: [ADDRESS_972838] been emplo yed for recent studies with other biologics and are considered “state -of-the-art” 
for studies in COPD ( 16, 17) . The selection of the dose of IMP and duration of study  treatment are 
explained in 
Section 4.[ADDRESS_972839] while significantl y reducing exacerbations and improving lung function in a 
population of severe corticosteroid- dependent asthmatics.
In the dupi[INVESTIGATOR_714329], doses of 200 mg q2w and 300 mg q2w demonstrated 
comparable efficacy  and safet y in reducing exacerbations and improving FEV 1in patients with 
moderate -to-severe asthma not chronicall y using concomitant oral corticosteroids (OCS). 
However, anal ysis of the exposure -response relationships using descriptive exposure quartile and 
model based anal yses for these two efficacy  endpoints showed that increasing dupi[INVESTIGATOR_208446] a greater effect for both efficacy  endpoints in patients with uncontrolled 
moderate -to-severe asthma. The lun g function improvement and severe exacerbation rate 
reduction approached a maximum at the exposure of 200 mg and 300 mg q2w, with a 5 to 9% 
greater reduction in exacerbations for 300 mg q2w. FEV 1response was also predicted to be better 
maintained over the dosing interval for 300 mg q2w. In severe OCS -dependent asthma patients, 
an exposure response relationship was noted at 300 mg q2w, with more patients achieving OCS -
free asthma control at the exposure range at 300 mg q2w (mean C trough approximately  70 mg/ L) 
than that at 200 mg q2w (mean C trough approximately  39 mg/L). Furthermore, the [ADDRESS_972840] majority  of patients and therefore a 
higher regimen is not expected to provide additional efficacy . 
Considering that the proposed COPD population to be enrolled in this study has the potential for 
significant risk for morbidity  and mortalit y associated with impairment of their lung function, 
similar to the patients in the OCS -sparing Phase 3 asthma study  (Study  EFC13691), the Sponsor is 
including the 300 mg q2w dose regimen to achieve the optimal benefit/risk ratio in this difficult 
COPD patient population .
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: [ADDRESS_972841] completed the study  if he/she has comple ted all phases of the 
study  including the end of study  visit.
The end of the stud y is defined as completion of the last patient last visit (the End of Study  Visit) 
which will occur at the end of a 12 -week safet y follow -up period for those patients who comp lete 
the study  as per protocol. 
For patients who permanently  discontinue the planned treatment, the recommended follow- up is 
described in Section 4.1.
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: [ADDRESS_972842] y:
Age
I 01. Participa nt must be ≥40 to≤80years of age , at the time of signing the informed consent.
Type of participant and disease characteristics
I 02. Participants with a phy sician diagnosis of COPD who meet the following criteria:
- Current or former smokers with a smoking history of ≥10 pack -years
-Moderate to severe COPD (post -bronchodilator FEV 1/FVC ≤70% and 
post-bronchodilator FEV 1% predicted >30% and ≤70%).
-Medical Research Council (MRC) Dy spnea Scale grade ≥2.
-
Patient- reported history  of signs and s ymptoms of chronic bronchitis (chronic 
productive cough) for 3 months in the y ear up to screening in the absence of other 
known causes of chronic cough.
-Documented history  of high exacerbation risk defined as exacerbation history  of ≥2
moderate* or ≥1 severe** within the y ear prior to inclusion.  
*Moderate exacerbations are recorded by [CONTACT_714380] s ystemic corticosteroids (intramuscular (IM), intravenous, or oral) and/or 
antibiotics. One o f the two required moderate exacerbations has to require the use of 
systemic corticosteroids.
**Severe exacerbations are recorded by [CONTACT_714381][INVESTIGATOR_059] / emergency  room / urgent care visit. 
-Background triple t herapy  (ICS+ LABA+ LAMA) for 3 months prior to randomization 
with a stable dose of medication for ≥1 month prior to Visit 1: (Double therapy : LABA 
+ LAMA allowed if ICS is contraindicated)
I 03. Evidence of T ype 2 inflammation: Patients with blood eosinophils ≥300 cells/microliter at 
Visit 1 (Screening).
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 31Weight
I 04. Body mass index (BMI) ≥16 kg/m2. 
Sex
I 05. Male or Female
Contraceptive use b y women should be consistent with local regulations regarding the methods of 
contraception for those participating in clinical studies.
a)Female participants: A female participant is eligible to participate if she i s not pregnant 
(see Appendix 4 [ Section 10.4] , not breastfeeding, and at least one of the following 
conditions applies:
Not a woman of childbearing potential (WOCBP) as defined in Appendix 4 
(
Section 10.4)
OR
A WOCBP who agrees to follow the contraceptive guidance in Appendix 4 
(Section
10.4) during the inter vention period and for at least [ADDRESS_972843] dose of study  intervention.
Informed Consent
I 06. Capable of giving signed informed consent as described in Appendix 1 ( Section
10.1.2) 
which includes compliance with the requirements and restrictions listed in the informed 
consent form (I CF)and in this protocol.
5.2 EXCLUSION CRITERIA  
Participants are excluded from the study  if any  of th efollowing criteria apply :
Study methodology
E 01. COPD diagnosis for less than 12 months prior to randomization
E 02. A current diagnosis of asthma according to the 2018 Global Initiative for Asthma (GINA) 
guidelines or other accepted guidelines; or an y history of asthma diagnosis  ≥ 40 y ears of 
age
E 03. Significant pulmonary  disease other than COPD (e.g. lung fibrosis, sarcoidosis, interstitial 
lung disease, pulmonary  hypertension, bronchiectasis, Churg -Strauss S yndrome etc) or 
another diagnosed pulmonary  or systemic disease associated with elevated peripheral 
eosinophil counts.
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 32E 04. Cor pulmonale, evidence of right cardiac failure
E 05. Treatment with ox ygen of more than 12 hours per d ay.
E 06. Hypercapnia requiring BiPAP
E 07. Acute exacerbation of COPD (AECOPD, as defined above in I 02) within [ADDRESS_972844] infection within 4 weeks prior to screening, or during the screening 
period.
E 09. History  of, or planned pneumonectom y or lung volume reduction surgery . Patients who are 
participating in the acute phase of a pulmonary  rehabilitation program, ie, who started 
rehabilitation <4 weeks prior to screening (Note: patients in the maintenance phase of a 
rehabilitation program can be included).
E 10.
Diagnosis of α -1 anti -trypsin deficiency
E 11. Inability  to follow the procedures of the study  (e.g., due to language problems, 
psychological disorders) or unable to read, understand and fill out a questionnaire or use an 
e-Diary  without any  help
E 12. Anti
-immunoglob ulin E (IgE) therap y (omalizumab) within 130 days prior to Visit 1 or 
any other biologic therapy  (including anti -IL5 mAb) or immunosuppressant to treat 
inflammatory  disease or autoimmune disease (e.g., rheumatoid arthritis, inflammatory  
bowel disease, prim ary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis, 
etc.) as well as other diseases within 2 months or 5 half- lives prior to Visit 1, whichever is 
longer
E 13. Exposure to another investigative drug (small molecules a s well as monoclonal ant ibodies ) 
within a time period prior to Visit 1 that is less than 6 months. The minimum interval since 
exposure to any  other (non -antibody) investigative study  medication is 30 day s prior to 
Visit 1 .
E 14. History  of systemic h ypersensitivity  or anaphy laxis to an y biologic therap y, including an y 
excipi[INVESTIGATOR_840]. 
E 15. Patients receiving medication or therap y that are prohibited as concomitant therap y (see 
Section 6.5).
E 16. Patient is the I nvestigator, or any  Sub-investigator, research assistant, pharmacist, study  
coordinator, other staff or relative thereof directl y involved in the conduct of the study
E 17. Clinically  significant abnormal electrocardiogram (ECG) at randomization that may  affect 
the conduct of the stud y in
the judgment of the investigator, prolonged QTc interval [male 
>450 msec, female >470 msec, Fredericia correction].
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 33E 18. A patient with a history  of clinically  significant renal, hepatic, cardiovascular, metabolic, 
neurologic, hematologic, ophthalmologic, resp iratory , gastrointestinal, cerebrovascular, 
substance and/or alcohol abuse, prior history  of malignancy  or active malignancy , 
including l ymphoproliferative diseases (except successfully- treated carcinoma in -situ of 
the cervix, non- metastatic squamous cell or basal cell carcinoma of the skin) within [ADDRESS_972845] that the patient has been adequatel y 
treated and can now start treatment with a biologic agent, in the medical judgment of the 
investigator and/or infectious disease specia list.
E 20. Acute m yocardial infarction < 6 months from screening visit
E 21. TIA or stroke < 6 months from screening visit
E 22. Hospi[INVESTIGATOR_714330] < [ADDRESS_972846] 6 months, e.g. 
antiarry thmics, antihy pertensives, and antidiuretics, etc. Dose modification of cholesterol -
modify ing agents and anticoagulants is allowed.
E 25. Cardiac arrhy thmias including paroxy smal (e.g. intermitte nt) atrial fibrillation are excluded. 
Patients with persistent atrial fibrillation as defined by [CONTACT_453572] 
6 months and controlled with a rate control strategy (i.e., selective beta blocker, calcium 
channel blocker, pacema ker placement, digoxin or ablation therapy ) and stable appropriate 
level of anticoagulation for at least 6 months may  be considered for inclusion.
E 26. Unstable ischemic heart disease or other relevant cardiovascular disorder such as 
pulmonary  embolism, deep ve in thrombosis within ≤6 months from enrollment that in 
Investigator's judgment may  put the patient at risk or negativel y affect the study  outcome.
E 27. Patients who are < 80% compliant with controller therapy  during screening 
E 28. Previous use of dupi[INVESTIGATOR_12458]
E 29. Females w ho are lactating, breastfeeding or who are pregnant.
E 30. Women of childbearing potential (pre- menopausal female biologicall y capable of 
becoming pregnant) who (also see Appendix 4, Section 10.4):
D
o not have a confirmed negative serum beta-hCG test at Visit [ADDRESS_972847] at Visit 2
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 34Who are not protected b y one following acceptable forms of effective contraception during 
the study :
oEstablished use of oral, injected or implanted o r inserted hormonal contraceptive.
oIntrauterine device (IUD) with copper or intrauterine sy stem (IUS) with 
progestogen
oBarrier contraceptive (condom, diaphragm or cervical vault caps) used with 
spermicide (foam, gel, film, cream or suppository ), if allowed by [CONTACT_714382] (eg, tubal occlusion, hy sterectomy  or bilateral salpi[INVESTIGATOR_1656] )
oMale sterilization with post- vasectom y documentation of the absence of sperm in 
the ejaculate; for female patients in the study , the vasectomized male partner 
should be the sole partner for that patient
oTrue abstinence in keepi[INVESTIGATOR_714331]; periodic abstinence ( eg, calendar, ovulation, sy mptothermal, post -
ovulation methods) is not an accepta ble method of contraception
Postmenopausal women (defined as at least 12 consecutive months without menses) are 
not required to use additional contraception
E 31. Diagnosed active parasitic infection (helminthes), suspected or high risk of parasitic 
infection, u nless clinical and (if necessary ) laboratory  assessments have ruled out active 
infection before randomization
E 32. History  of HIV infection or positive HIV 1/2 serology  at Visit 1
E 33. Known or suspected history  of immunosuppression, including history  of invasive 
opportunistic infections (e.g. tuberculosis, histoplasmosis, listeriosis, coccidioidomy cosis, 
penumocy stosis, aspergillosis), despi[INVESTIGATOR_12468]; or unusually  frequent, 
recurrent or prolonged infections, per investigator’s judgment.
E 34. Evidence of acu te or chronic infection requiring treatment with antibacterials, antivirals, 
antifungals, antiparasitics, or antiprotozoals within [ADDRESS_972848] received antiviral treat ment 
(e.g., influenza receiving only  symptomatic treatment) 
E 35. Live, attenuated vaccinations within 4 weeks prior to Visit 1 o
r planned live, attenuated 
vaccinations during the study ; see Section 10.7 (Appendix 7) for list of prohibited live, 
attenuated vaccines
E 36. Patients with active autoimmune disease or patients using immunosuppressive therap y for 
autoimmune disease (e.g. inflammatory  bowel disease, primary  biliary  cirrhosis, sy stemic 
lupus ery thematosus, multiple sclerosis, etc.)
E 37. Patients with any  of the following result at screening:
Positive (or indeterminate) HBsAg or
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 35Positive IgM HBc Ab or
Positive total HBc Ab confirmed b y positive HBV DNA or
Positive HCV Ab confirmed by  [CONTACT_125448]
E 38. Clinically  significant laboratory  tests at screening/randomization (Visit 1):
Alanine transaminase (ALT) >3 times upper limit of normal range (ULN)
Hemoglobin <10g /100 mL  for male and < 9g/ 100 mL  for female
Platelets <100 000/mm3,
Creatinine ≥150 μmol/L
E 39. Patients on macrolide (e.g. azithromy cin) therapy , unless on stable therap y for > 12months
E 40. Patient who has withdrawn consent before enrollment/randomization
E 41. Despi[INVESTIGATOR_56372], enrollment/randomization is stopped at the study  level.
5.3 LIFESTYLE CONSIDERATIONS
Not applicable .
5.4 SCREEN F AILURES
Screen failures are defined as participants who consent to participate in the clinical study  but are 
not subsequently  randomly  assigned to IMP. A minimal set of screen failure information is 
required to ensure transparent reporting of screen failure participants to meet the Consolidated 
Standards of Reporting Trials (CONSORT) publishing requirements and to respond to queries 
from regulatory authorities. Minimal information includes demography , screen failure det ails, 
eligibility  criteria, and any  serious adverse event (SAE).
Patients who are eligible for rescreening may  be rescreened once for any  reason. I n the case of 
technical malfunction of equipment, the patient may be rescreened.  Patients who fail the 
exclu sion criteria may  be rescreened during the open screening period of the study ; a different 
patient identification number will be issued.
Retesting of eosinophil values is allowed up to three times during the screening period to meet 
inclusion criteria for showing eosinophil count ≥300 cells/microliter ( I 03) before randomization. 
A patient who is unable to complete a successful spi[INVESTIGATOR_714332] t he screening period of the stud y.
There is no requirement for a waiting period between the screen -failure date and the rescreening 
date. The IVRS/I WRS report will flag rescreened patients. Patients that are rescreened must sign a 
new consent form and all V isit [ADDRESS_972849] be repeated .
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 366 STUDY INTERVENTION
Study  intervention is defined as an y investigational intervention (s), marketed product(s), placebo, 
or medical device(s) intended to be administered to a study  participant according to the study  
protoc ol.
6.1 STUDY INTERVENTION (
S) ADMINISTERED
Table 2 -Overview of study interventions administered
Study intervention name [CONTACT_125502][INVESTIGATOR_12458] 300 mg q2w Placebo q2w
Dosage formulation Dupi[INVESTIGATOR_12458] 300 mg for SC 
administration is supplied as 150 
mg/mL solution in 2.25 mL prefilled 
glass syringes to deliver 300 mg in 
2.0 mLPlacebo for dupi[INVESTIGATOR_714333] -filled 
syringe to deliver 2 mL which will 
match dupi[INVESTIGATOR_12458] 300 mg.
Unit dose strength(s)/Dosage level(s) 300mg Not applicable
Route of administration Subcutaneous injection sites should 
alternate between the upper thighs, 4 
quadrants of the abdomen or the 
upper arms, so that the same site is 
not injected twice during consecutive 
visitsSubcutaneous injection s ites should 
alternate between the upper thighs, 4 
quadrants of the abdomen or the upper 
arms, so that the same site is not 
injected twice during consecutive visits
Dosing instructions Every 14 ± 3days Every 14 ± 3days
Packaging and labeling Dupi[INVESTIGATOR_714334] l be supplied as one 
glass pre -filled syringe packed in a 
patient kit box.  Both glass pre -filled 
syringe and box will be labeled as 
required per country requirement.Placebo will be supplied as one glass 
pre-filled syringe packed in a patient kit 
box.  Bo th glass pre -filled syringe and 
box will be labeled as required per 
country requirement.
6.1.[ADDRESS_972850](S)
The investigational medicinal product (IMP) is administered every 14±3 days (q2w) during the 
52-week treatment period ( Table 2). 
Investigational medicinal product (IMP) will be administered by  [CONTACT_737]/health care 
professional or designee following clinic procedures and blood collection. Patients should be 
monitored for at least [ADDRESS_972851] train the patient at an 
on-site visit during the treatment period.  At this visit the patient w ill perform the injection under 
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: [ADDRESS_972852] be documented in the patient’s 
study  file.  At subsequent study  visits, patients are trained to self- inject IMP, and the patients are 
allowed to self -injec t IMP at home after [ADDRESS_972853] 30 minutes 
(or longer per country  specific or local site -specific requirements) following injection.
For doses not given at the study  site, diaries will be provided to record information related to the 
injections. The diary  will be kept as source data in the patient’s study  file.
6.1.[ADDRESS_972854](S)
Background therapy 
At Screening Visit 1, all patients must be on triple background therap y, for 3 months prior to Visit 
2/Randomization and at a stable dose of medication for at le ast 1 month prior to the 
Screening/Visit 1, including triple therap y: LABA + LAMA +I CS (Double therapy : LABA + 
LAMA allowed if ICS is contraindicated).
Formulation: dry  powder inhaler (DPI), metered dose inhaler (MDI) or pocket nebulizer
Route(s) of admini stration: Oral inhalation
Dose regimen: As prescribed
Throughout the stud y, patients should continue their established background therap y for COPD, 
including dose and regimen.
Patients must be willing to stay  on their established background medication for COPD throughout 
the duration of the treatment period. After successful management of an acute exacerbation of 
COPD (e.g. with oral corticosteroids and/or antibiotics), all efforts should be made to resume the 
initial background COPD treatment regimen if in the investigator’s opi[INVESTIGATOR_714335]. Background medications should not be adjusted during Screening. After [ADDRESS_972855] -treatment period. 
Background therap y will be supplied by [CONTACT_2728]’s local affiliate as locall y required or b y sites.  
Reimbursement will be provided when deemed necessary and as per country regulation.
Reliever Medication
Reliever medications will be supplied by  [CONTACT_714383]’s local affilia te as locally  required.
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 38Patients may  administer albuterol/salbutamol or levalbuterol/levosalbut amol or ipratropi[INVESTIGATOR_208454]/short-acting β agonists [SABA ] combinations or terbutaline as needed during the 
study . Nebulizer solutions may  be used as an alternative delivery  method.
Formulati on: MDI, nebulizer solutions or DPI
[INVESTIGATOR_714302]: oral inhalation
Dose regimen: as prescribed
Study  personnel will convert salbutamol/albuterol nebulizer and levosalbutamol/levalbuterol 
nebulizer use as shown on the following tables:
Table 3
-Reliever medication -Salbutamol/A lbuterol nebulizer solution
Salbutamol/Albuterol Nebulizer Solution -Total Daily Dose (mg) Number of Puffs *
2.5 4
5.0 8
7.5 12
10 16
*Conversion factor: salbutamol/albuterol nebulizer solution ( 2.5 mg) corresponds to 4 puffs
Example of salbutamol/albuterol nebulizer -to-puff conversion: Patient received 
3salbutamol/albuterol nebulizer treatments (2.5 mg/treatment) between 7 and 11 AM. Total 
daily  = 7.5 mg or 12 puffs.
Table 4 -Reliever medication -Levosalbutamol/Levalbuterol nebulizer solution
Levosalbutamol/Levalbuterol Nebulizer Solution -Total Daily Dose (mg) Number of Puffs *
0.63 2
1.25 4
2.5 8
3.75 12
5 16
*Conversion factor:  lev osalbutamol/levalbuterol nebul izer solution (1.25 mg) corresponds to 4 puffs
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 39Example of levosalbutamol/levalbuterol nebulizer- to-puff conversion: Patient received 
3lev
osalbutamol/levalbuterol nebulizer treatments (1.25 mg/treatment) between 7 and 11 AM. 
Total daily  = 3.75 mg or 12 pu ffs. 
Table 5 -Reliever medication - Lpratropi[INVESTIGATOR_208405]/short -acting β agonists [SA BA] 
nebulizer solutions
Total Daily Dose of Ipratropi[INVESTIGATOR_1890] (mg) in Ipratropi[INVESTIGATOR_714336]/SABA Nebulizer Solutions Number of Puffs *
0.5 4
1.0 8
1.5 12
2.0 16
*Conversion factor: ipratropi[INVESTIGATOR_714337]/short -acting β agonists (SABA)  nebulizer solution (with 0.5 mg 
Ipratropi[INVESTIGATOR_1890]) corresponds to 4 puf fs
Example of ipratropi[INVESTIGATOR_208411]/SABA nebulizer -to-puff conversion: Patient received 
3 ipratropi[INVESTIGATOR_208411]/SABA nebulizer treatments (0.5 mg Ipratropi[INVESTIGATOR_1890]/treatment) 
between 7 and 11 AM. Total daily  = 1.5 mg or 12 puffs.
6.2 PREP ARAT ION/HA NDLING /STORA GE/A CCOUNTA BILITY
Storage and handling
Investigators or other authorized persons (e.g., pharmacists) are responsible for storing the 
IMP/noninves tigational medicinal product (NIMP) in a secure and safe place in accordance with 
local regulations, labeling specifications, policies, and procedures. 
Control of I MP storage conditions, especially  control of temperature (eg, refrigerated storage) and 
information on in- use stability  and instructions for handling the [COMPANY_011] compound must be 
managed according to the rules provided b y the Sponsor in the pharmacy manual. 
The expi[INVESTIGATOR_400678] (when required by  [CONTACT_714384]), and
storage conditions are written on the I MP labels.
1. The Investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study  intervention and NIMP received and any  
discrepancies are reported and resolved before use of the study  intervention.
2.Only  participants enrolled in the study  may  receive study  intervention and only  authorized 
site staff may  supply  or administer study  intervention. All study  intervention and NIMP 
must be stored in a secure, environmen tally controlled, and monitored (manual or 
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 40automated) area in accordance with the labeled storage conditions with access limited to 
the Investigator and authorized site staff.
3. The Investigator, institution, or the head of the medical institution (where applicable) is 
responsible for stud y intervention and NIMP accountability , reconciliation, and record 
maintenance (ie, receipt, reconciliation, and final disposition records).
4.Further guidance and information for the final disposition of used and unused study
interventions are provided in a Pharmacy  manual. 
Preparation of IMP
Dupi[INVESTIGATOR_208456] -filled sy ringes will be dispensed to the patients.
Responsibilities
The Investigator, the hospi[INVESTIGATOR_98341], or other personnel allowed to st ore and dispense the 
IMP/NIMP will be responsible for ensuring that the IMP/NI MP used in the clinical trial is 
securel y maintained as specified b y the Sponsor and in accordance with applicable regulatory 
requirements.
All IMP/NIMP will be dispensed in acco
rdance with the I nvestigator's prescription and it is the 
Investigator's responsibility  to ensure that an accurate record of IMP/NIMP issued and returned is 
maintained. For doses not given at study site, the home dosing diary will be used to record 
injecti ons. 
Any quality  issue noticed with the receipt or use of an IMP/NI MP(deficiency  in condition, 
appearance, pertaining documentation, labeling, expi[INVESTIGATOR_320], etc) must be promptly  notified to 
the Sponsor. Some deficiencies may  be recorded through a com plaint procedure (see 
Section 8.3.9).
A potential defect in the quality  of IMP/NIMP may  be subject to initiation of a recall procedure 
by [CONTACT_1034]. In this case, the Investig ator will be responsible for promptly  addressing any  
request made b y the Sponsor, in order to recall the IMP/NI MP and eliminate potential hazards.
Under no circumstances will the I nvestigator supply  IMP/NIMP to a third party  (except for DTP 
shipment, for w hich a courier compan y has been approved b y the Sponsor), allow the 
IMP/NIMP/device to be used other than as directed by  [CONTACT_13129], or dispose of 
IMP/NIMP/device in an y other manner.
6.3 MEA SURES TO MINIM IZE BIA S: RA NDOMIZAT ION A ND BLI
NDING
6.3.[ADDRESS_972856] will be generated centrally  by [CONTACT_714385]. The 
IMPs (dupi[INVESTIGATOR_181150]) will be packaged in accordance with the list. The [COMPANY_011] 
Clinical Supply  Chain team will provide the randomized treatment kit number list and the Study  
Biostatician will provide the randomization scheme to the centralized treatment allocation sy stem 
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 41(Interactive Voice Response Sy stem/Interactive Web Response Sy stem [IVRS/I WRS]). This 
centralized treatment allocation sy stem will generate the patient randomization list according to 
which it will allocate the IMPs to the patients. The Investigator obtains treatment kit number at 
randomization and subsequent scheduled visits via an IV RS/IWRS that will be available 24 hours 
a day . Patients will be randomized in a 1:1 ratio to receive SC administrations of either:
Dupi[INVESTIGATOR_12458] 300 mg q2w
Matching placebo for dupi[INVESTIGATOR_12458] q2w.
Randomization will be stratified b y countr y and by  [CONTACT_714379]  (yes or no). 
Investigational medicinal products will be dispensed at the study  visits summarized in SoA 
(Section 1.3 ). 
Returned IMP from the patient’s home should not be re -dispensed to the participants.
6.3.[ADDRESS_972857] the blind, each treatment kit of 2 mL  (dupi[INVESTIGATOR_12458] / placebo) glass pre -filled sy ringes will 
be prepared such th at the treatments (dupi[INVESTIGATOR_125368]) are identical and 
indistinguishable and will be labeled with a treatment kit number. 
In accordance with the double -blind design, stud y patients, I nvestigators, and study  site personnel 
will remain bli nded to study  treatment and will not have access to the randomization arm or to the 
IMP content (dupi[INVESTIGATOR_24885]) except under circumstances d
escribed in Section 6.3.3.
6.3.[ADDRESS_972858] only  be broken in circumstances when knowledge of the IMP is 
required for treating the patient. 
Code breaking can be performed at an y time b y using the proper module of the IVRS/I WRS 
and/or by  [CONTACT_714386]. If the blind is 
broken, the Investigator must document the date, time of day , and reason for code breaking. 
Patient withdrawal will only  occur when the code break call is made at the site level, not the study  
level. This means that if the Emergency  Unblinding transaction is performed by  [CONTACT_737] 
(ie, at the site level), then the patient will be withdrawn from treatment. However, if the 
Emergency  Unblinding transact ion is performed by
 [CONTACT_714387] y Officer (GSO) (ie, at the 
study  level, as the GSO is not site based), then the patient will not be withdrawn from treatment.
Patients who are withdrawn from treatment should be encouraged to remain in the study  and the
Investigator should discuss with them the key  visits to attend (see Section 7.2).
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: [ADDRESS_972859] will also keep accurate records o f the quantities of the I MP/NIMP 
received, dispensed, used, unused and returned/destroy ed. The product accountability  and 
inventory  form/sy stem is to be updated each time IMP/NIMP is dispensed. It must be established 
with the I nvestigator or other personne l designated by  [CONTACT_714388]. The study  monitor will periodically check the supplies of 
the IMP held by  [CONTACT_714389] .
Treatment kit n umber has to be recorded on the appropriate page of the electronic Case Report 
Form (eCRF) and also on the product accountability and inventory  form/s ystem. 
All used, partially  used, or unused treatments will be destroy ed at each respective site, after 
accountability  and reconciliation have been performed. The site must not destroy  the unused 
IMP/NIMP unless the Sponsor provides written authorization. Confirmation of destruction will be 
provided to the Sponsor.
6.5 CONCOMITA NT THERA PY
Any medication or vaccine (including over -the-counter or prescription medicines, vitamins, 
and/or herbal supplements) that the participant is receiving at the time of enrollment or receives 
during the stud y must be recorded along with:
Reason for use
Dates of administration includ ing start and end dates
Dosage information including dose and frequency
The following concomitant medications are not permitted during the stud y from screening 
onwards:
Use of an y biologic agent within 5 half- lives of that compound before study entry (6 
months if half- live is not known) and during the course of the study .
Use of PDE4 inhibitors (roflumilast) and of theophy lline during the course of the study  
unless stable > 6 months prior to screening visit.
New chronic use of macrolide antibiotics (e.g. az ithromy cin) with the exception of 
AECOPD , in which case macrolides may be used up to 28 day s. 
Systemic immunosuppressants (eg, methotrexate, any  anti- TNF mAbs, B and/or T -cell 
targeted immunosuppressive therapi[INVESTIGATOR_014]) 
Intravenous immunoglobulin (I VIG) thera py
Live attenuat ed vaccines, refer to Appendix 7 ( Section 10.7)
Beta-adrenergic receptor blockers (except for a selective beta -1 adrenergic receptor 
blocker used with dose stable 1 month prior to Visit 1)
Other investigational drugs
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 43Note: The following is a list of permitted concomitant medications during the study
Maintenance treatment of COPD with I CS, LABA, LAMA, at a stable dosage, are allowed 
during the stud y
Systemic corticosteroids in case of acute exacerbation up to a maximum of 6 weeks
Rescue medication with SABA or short acting antimuscarinics (e.g. atrovent)
6.6 DOSE MODIFICA TION
Not applicable.
6.7 INTERVENTION AFTER THE END OF THE STUDY
Not applicable.
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 447 DISCONTINUA TION OF STUDY INTERVENTION AND 
PARTICIPA NT DISCONTI NUA TION /WITHDRA WAL
Withdrawal of consent for treatment (ie, treatment discontinuation at patient request) should be 
distinguished from (additional) withdrawal of consent for follow -up visits and from withdrawal of 
consent for non-p atient contact [CONTACT_6492] -up (eg, medical record checks). The site should document 
any case of withdrawal of consent.
7.1 DISCONTINUA TION OF S TUDY INTERVENTION
The IMP should be continued whenever possible. 
In case the IMP is stopped, it should be determined whe ther the stop can be made temporarily ; 
permanent IMP discontinuation should be a last resort. Any  IMP discontinuation must be fully  
documented in the eCRF.
7.1.[ADDRESS_972860] of criteria for permanent discontinuation of study intervention
All efforts should be made to document the reason(s) for discontinuation of study  intervention and 
this should be documented in the eCRF.
Patients must be withdrawn from the stud y for the following reasons:
At their own request or at the request of their legally  authorized representative (legall y 
authorized representative means an individual or judicial or other body  authorized under 
applicable law to consent on behalf of a prospective patient to the patient's participation in 
the procedu re(s) involved in the research).
If, in the Investigator's opi[INVESTIGATOR_1649], continuation in the study  would be detrimental to the 
patient's well -being.
At the specific request of the Sponsor.
In the event of a protocol deviation, at the discretion of the Investiga tor or the Sponsor.
Any code broken requested by  [CONTACT_714390].
Pregnancy
Anaph ylactic reactions or sy stemic allergic reactions that are related to IMP and require 
treatment.
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 45Diagnosis of a ma lignancy  during study , excluding carcinoma in situ of the cervix, or 
squamous or basal cell carcinoma of the skin.
Any opportunistic infection, such as TB or other infections whose nature or course may  
suggest an immunocompromised status ( see Section 10.16, Appendix 16).
Serum ALT >[ADDRESS_972861] and Total Bilirubin > 2ULN ( see Section
10.6, Appendix 6).
Serum ALT > [ADDRESS_972862] if baseline ALT ≤ [ADDRESS_972863] or ALT >[ADDRESS_972864] if baseline ALT > [ADDRESS_972865] ( seeSection
10.6, Appendix 6).
Any abnormal laboratory value or ECG parameter will be immediatel y rechecked for 
confirmation before making a decision of permanent discontinuation of the IMP for the concerned 
patient.
See the SoA 
(Section 1.3.2 ) for data to be collected at the time of inte rvention discontinuation and 
follow -up and for an y further evaluations that need to be completed.
Handling of participants after permanent study intervention discontinuation
Patients who discontinue the study  intervention prematurel y (prior to completing t he 52 -week 
treatment period) will perform, as soon as possible, the ETD visit with all assessments normally  
planned for the EOT visit (Visit 16), to assure a complete clinical assessment in close temporal 
proximity  to the premature termination of study  treatment is available. In addition, to allow 
assessment of patient outcomes over the stipulated study  period, patients will be asked and 
encouraged to complete all remaining stud y visits, and participate in all safety follow -up 
assessments according to the v isit schedule with a ± 5 day  window. For these patients the 
assessment schedule will be reduced ( seeSection 1.3.2) and visits during the planned treatment 
period may  be conducted by  [CONTACT_648] (exc ept for planned EOT) if patient is unable to come in for a 
site visit. Assessments not completed via phone should be performed at the next scheduled visit.
Patients will be followed
-up according to the study  procedures specified in this protocol up to the 
scheduled date of study  completion (i.e. EOS , see Section 1.3), or up to recovery  or stabilization 
of an y AE to be followed -
up as specified in this protocol, whichever comes last.
Patients who discontinue earl y from treatment may be asked to return to the clinic to have 
additional antidrug antibody  (ADA) samples collected for anal ysis based on the overall 
assessment of antibod y titers and/or clinical presentation at the time of discontinuation.
All cases of permanent discontinuation of study intervention should be recorded by  [CONTACT_714391].
Temporary discontinuation of study  intervention 
Temporary discontinuation of study  intervention may  be considered by  [CONTACT_941] I nvestigator because of 
AEs. Reinitiation of treatment with the I MP will be done under close and appropriate clinical/and 
or laboratory  monitoring once the Investigator will have considered according to his/her best 
medica l judgment that AE is sufficiently  resolved and unlikely  to recur after resuming therap y 
with I MP.
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 46In addition, the following conditions(s) will be causes for temporary  discontinuation of study  
intervention:
Infections or infestations that do not respond t o medical treatment 
Any laboratory  abnormality  that meets temporary  treatment discontinuation criteria as per 
Appendix 6 ( Section 10.6 )
If a patient is unable to return to clin
ic for a given visit within the specified visit window, patient 
should follow -up with all visit follow -up procedures planned for the subsequent visit (excluding 
randomization and EOT).
If the patient misses more than [ADDRESS_972866] be recorded b y the 
Investigator in the eCRF. Following a temporary  interruption or missed dose, the IMP treatment 
should be reinitiated at t he next scheduled visit, maintaining the original dose.
7.2 PARTICIPA NT DISCONTI NUA TION/ WITHDRAWA L FROM THE STUDY
A participant may  withdraw from the study  at an y time at his/her own request, or may  be 
withdrawn at an y time at the discretion of the Investigato r for safety , behavioral, compliance, or 
administrative reasons.
If the participant withdraws consent for disclosure of future information, the Sponsor may  
retain and continue to use an y data collected before such a withdrawal of consent.
If a participant withdraws from the study , he/she may  request destruction of any  samples 
taken and not tested, and the I nvestigator must document this in the site study  records. 
See SoA ( Section 1.3.2) for dat a to be collected at the time of study  discontinuation and 
follow -up and for an y further evaluations that need to be completed.
Patients who withdraw from study  treatment (prior to completing the planned duration of IMP 
treatment) will perform the ETD visi t and will be asked and encouraged to complete all remaining 
study  visits. Patients who withdraw from the study during the post
-treatment phase should be 
encouraged to return for the EOS visit ( for details see Section 1.3.2 and Section 7.1.1). The value 
of all their study  
data collected during their continued involvement will be emphasized as 
important to the public health value of t he stud y.
All study  withdrawals should be recorded b y the Investigator in the appropriate screens of the e -
CRF, IVRS/I WRS and in the patient’s medical records. In the medical record, at least the date of 
the withdrawal and the reason should be documented.
In addition, a patient may  withdraw his/her consent to participate in the study . Withdrawal of 
consent for intervention should be distinguished from withdrawal of consent for follow -up visits 
and from withdrawal of consent for non -patient contact [CONTACT_6492] -
up, eg, medical record checks. The 
site should document any case of withdrawal of consent.
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: [ADDRESS_972867] withdrawn from the stud y cannot be rerandomized (treated) in the study. 
Their inclusion and intervention numbers must not be reused. 
If possible, the patients are assessed using the procedure normall y planned for the end- of-study  
visit including a sy stemic drug concentration sample, if appropriate, and the Post treatment Period 
Visits.
7.[ADDRESS_972868] be taken if a participant fails to return to the clinic for a required stud y 
visit:
The site must attempt to con tact the participant and reschedule the missed visit as soon as 
possible and counsel the participant on the importance of maintaining the assigned visit 
schedule and ascertain whether or not the participant wishes to and/or should continue in 
the study .
Before a participant is deemed lost to follow up, the Investigator or designee must make 
every  effort to regain contact [CONTACT_6635] (where possible, 3 telephone calls and, if 
necessary , a certified letter to the participant’s last known mailing addr ess or local 
equivalent methods). These contact [CONTACT_13140]’s 
medical record.
Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study.
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 488 STUDY A SSESSMENTS A ND PROCEDUR ES
Study  procedures and their timing are summarized in the SoA ( Section 1.3). Protocol waivers or 
exemptions are not allowed.
Immediate safety  concerns should be discussed with the Sponsor immediately
 upon 
occurrence or awareness to determine if the participant should continue or discontinue 
study  intervention.
Adherence to the stud y design requirements, including those specified in the SoA, is 
essential and required for study  conduct.
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The Investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility  or record reasons for 
screening failure, as applicable. 
Procedures conducted as part of the participant’s routine clinical management (eg, blood count)
and obtained before signing of the ICF may  be utilized for screening or baseline purposes 
provided the p rocedures met the protocol
-specified criteria and were performed within the time 
frame defined in the SoA ( Section 1.3 ).
8.1 EFFICA CY ASSESSMENTS
8.1.1 Disease- specific efficacy measures
[IP_ADDRESS] Severity ofCOPD exacerbations as defined by [CONTACT_760]
“Moderate exacerbations” are recorded b y the Investigator and defined as AECOPD that require 
either s ystemic corticosteroids (such as intramuscular, intravenous or oral) and/or antibiotics. 
“Severe exacerbations” are recorded by [CONTACT_208529][INVESTIGATOR_059], emergency  medical care visit or resulting in death.
All other exacerbations will be classified as “mild”.
For both moderate and severe events to be counted as separate events, they  must be separated b y 
at least 14 day s.
Clinical symptoms of exacerbations of COPD
In addition to the protocol -defined exacerbations of COPD listed above, clinical signs and 
symptoms of exacerbations of COPD will be captured in the eC RF (including, but not limited to 
increase in dy spnea, increase in wheezing, increase in cough, increase in sputum volume and/or 
increase in sputum purulence).
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 49Management of exacerbations of COPD
Exacerbations of COPD should be treated as deemed necessary  by [CONTACT_093]. After 
successful management of an acute exacerbation of COPD (e.g. with oral corticosteroids and/or 
antibiotics), all efforts should be made to resume the initial background COPD treatment regimen 
if in the investigator’s opi[INVESTIGATOR_714338]. After 1 severe or 2 moderate 
exacerbations of COPD, dose adjustments in background therap y will be permitted for s ymptom 
control and as needed for the remainder of the trial period.
Protocol defined COPD exacerbation events are col lected as efficacy  endpoints via the 
exacerbation eCRF. These events should not be reported as AEs unless they fulfill a seriousness 
criterion.
[IP_ADDRESS] Spi[INVESTIGATOR_714339] (ERS)/American Tho
racic Society  (ATS) guidelines (22)and prior to 
administration of investigational product. 
For pre -bronchodilator measured parameters, including FEV 1, FVC and forced expi[INVESTIGATOR_11311] 
(FEF) 25% -75%, spi[INVESTIGATOR_714340] a wash out period of bronchodilators 
according to their action duration, for example, withholding the last dose of salbutamol/albuterol 
or levosalbutamol/levalbuterol for at least [ADDRESS_972869] 
12 hours (ultra -long acting LABA like vilanterol should be withheld for at least 24 hours), 
withholding the last dose of ipratropi[INVESTIGATOR_208461] [ADDRESS_972870] 24 hours. This will be verified before performing the measurements. 
Note: When both pre- and post -bronchodilator spi[INVESTIGATOR_714341], the post -bronchodilator 
spi[INVESTIGATOR_714342] (ie, 30 
minutes for albuterol or another SABA).
At all visits, spi[INVESTIGATOR_714343]; afternoon/evening is 
allowable in the exceptional circumstance when morning spi[INVESTIGATOR_125375]; 
spi[INVESTIGATOR_714344] . 
Current smokers need to be reminded not to smoke for at least [ADDRESS_972871] spi[INVESTIGATOR_181201], including calibration, will be used to 
perform spi[INVESTIGATOR_714345], whe never possible, the same person should perform the 
measurements.
Three measurements fulfilling the ATS acceptability  and repeatability  criteria should be obtained 
at every  visit, if possible. 
Optional home spi[INVESTIGATOR_714346] . Patients will 
receive documented in -clinic training for use of ambulatory  at-home spi[INVESTIGATOR_714347]. 
Further details on spi[INVESTIGATOR_714348] a separate operational manual provided to the 
sites.
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page [IP_ADDRESS] Optional Sputum Coll ection
A subset of study  sites will be selected to perform evaluations of induced/spontaneous sputum, 
and patients at these selected sites will have the option to participate in this assessment. Sputum 
induction is a relatively  noninvasive method to obtain sputum for cell or fluid phase inflammatory  
indices, culture or cy tology . It is performed with an aerosol of normal or hypertonic saline 
generated b y an ultrasonic nebulizer. As this aerosol is a potential bronchoconstrictive stimulus, it 
is made safe b y pretreatment with salbutamol and inhalation in a dose response manner. 
Collection will be performed according to protocol flowchart .
8.1.2 Clinical outcome assessments
[IP_ADDRESS] Patient reported outcome questionnaires
At screening (Visit 1), patients will be issued an ele ctronic diary . Patients will be instructed and 
trained b y members of the clinical staff on the use of the device, and written instructions on the 
use of the electronic device will be provided to the patients. Recorded information is downloaded 
from this de vice on the other indicated day s (Section 1.3). 
On a dail y basis during screening and treatment, the patient will use an electronic diary to:
Respond to the COPD exacerbation and s ymptom scale questions of the EXACT tool.  
Record use of established controller inhalation therap y.
The electronic diary  will be used for other patient related questionnaires such as SGRQ from the 
protocol. 
In the Post IMP Treatment Period, the patient's response in 
the electronic diary  will not be 
recorded dail y; electronic questionnaires will only  be administered at on- site visits as outlined in 
the SoA.
Patient- reported outcome questionnaires at a site/visit should be completed prior to any  other 
assessments or procedures.
[IP_ADDRESS].1 St. George's Respi[INVESTIGATOR_6015] (SGRQ)
The St. George's Re spi[INVESTIGATOR_21606] (SGRQ [( 23, 24) ]) is a 50 -item questionnaire 
designed to measure and quantify  health status in adult patients with chronic airflow limitation. A 
global score ranges from 0 to 100. Scores by  [CONTACT_674020]: 
Symptoms, Activity  and Impacts (Psy cho-social) as well as a total score. Lower score i ndicates 
better quality  of life (QoL) (see Appendix 10: St. George's Respi[INVESTIGATOR_21606], 
Section
10.10). 
The first part ("S ymptoms") evaluates s ymptomatology , including frequency  and severity  of 
cough, sputum production, wheeze, breathlessness and the duration and frequency  of attacks of 
breathlessness or wheeze. The second part has two components: "Activity " and "I mpacts". The 
"Activit y" section addresses disturbances t
o patients’ daily  physical activities. The "Impacts" 
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: [ADDRESS_972872] on patients’ daily  life and ps ycho -
social functions (eg daily life activities and functioning, emplo yment, ph ysical functioning, 
emotional i mpact, stigmatization, and patients’ perceptions when treated). The recall period of the 
questionnaire is over the past 4 weeks. 
Psychometric testing has demonstrated its repeatability , reliability  and validity . Sensitivity  has 
been demonstrated in clinic al trials. A minimum change in score of 4 units was established as 
clinically  relevant after patient and clinician testing. The SGRQ has been used in a range of 
disease groups including asthma, COPD and bronchiectasis.
[IP_ADDRESS].2 Exacerbations of chronic pulmonary di sease tool (EXACT)
The EXACT tool quantifies and measures exacerbations of COPD and assesses the sy mptomatic 
manifestations of these COPD exacerbations ( see Appendix 12: Exacerbations of Chronic 
obstructive pulmonary  disease tool [EXACT], Section 10.12). The instrument is a daily  diary  
composed of a total of 14 items representing the following doma
ins:
Breathlessness (5 items),
Cough and sputum (2 items),
Chest sy mptoms (3 items) ,
Difficulty  bringing up sputum (1 item),
Tired or weak (1 item),
Sleep disturbance (1 item), and
Scared or worried (1 item).
Development and validation history of the tool is consistent with guidelines proposed by  [CONTACT_1622], 
EMA and well -known measurement principles.  The EXACT total score assesses COPD 
exacerbations. The higher the score, the more severe are the s ymptoms. 
The Evaluating Respi[INVESTIGATOR_244774] (E -RS) in COPD (E -RS: COPD) scale is a part of the 
EXACT tool. I t is a derivative instrument used to measure the effect of treatment on the severit y 
of respi[INVESTIGATOR_714349].  The E -RS utilizes the [ADDRESS_972873]. The RS -Total score represents respi[INVESTIGATOR_714350] y, 
overall. Three subscale s can be used that assess: 1) breathlessness (RS -Breathlessness), 2) cough 
and sputum (RS -Cough and Sputum), and 3) chest -related s ymptoms (RS -Chest Sy mptoms). The 
higher the score the more severe are the s ymptoms.
[IP_ADDRESS].3 The 5 -level Euro Quality of Life -5 Dimens ion questionnaire (EQ -5D-5L)
EQ-5D- 5L is a standardized health -related QoL questionnaire developed by  [CONTACT_159872] a simple, generic measure of health for clinical and economic appraisal (17). EQ 
5D is designed for self -completion by [CONTACT_1962]. The EQ -5D consists of a descriptive s ystem and 
the EQ Visual Analog Scale (VAS). The descriptive sy stem comprises five dimensions: mobility , 
self-care, usual activities, pain/discomfort and anxiety /depression. Each dimension has 5 levels: 
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 52no problems, slight problems, moderate problems, severe problems and extreme problems. The 
EQ VAS records the patient’s self
-rated health on a vertical visual analogue scale, (Appendix 14, 
see Section 10.14).
[IP_ADDRESS] Other clinical outcome assessments
[IP_ADDRESS].1 Body -Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index (BODE 
Index)
The BODE Index is a composite measure composed of a Performance Outcome Measure, a 
Patient
-Reported Outcome Measure and a Biomarker. The BODE Index is a multidimensional 
grading s ystem to assess the respi[INVESTIGATOR_714351] (25).It comprises 4 
domains: 1) Degree of pulmonary  impairment (FEV 1); 2) Patient’s p erception of sy mptoms 
(mMRC); and 2 independent domains: the 6 Minute Walking Distance (6MWD) and the Bod y
-
Mass I ndex (BMI). Each domain can be scored independentl y; the global score ranges from 0 to 
10, with a higher score indicating a higher risk of deat h (see Appendix 13, Section 10.13).
8.[ADDRESS_972874] (AESI ), will be collected at 
every  visit. The assessments for AE, SAE and AESI  are described in Section 8.3.
Planned time points for all safety  assessments are provided in the SoA ( Section 1.3).
8.2.1 Physical examinations
A complete ph ysical examination will include skin, nasal cavities, ey es, ears, respi[INVESTIGATOR_696] , 
cardiovascular, gastrointestinal, neurological, l ymphatic, and mu sculoskeletal sy stems. All 
deviations from normal will be recorded, including those attributable to the patient’s disease.
Refer to 
Section 1.3 for the schedule of phy sical examinations perform ed throughout this study .
Investigators should pay  special attention to clinical signs related to previous serious illnesses or 
signs of infection. 
Any new clinicall y significant finding or worsening of previous finding should be reported as a 
new adverse event.
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 538.2.2 Vital signs
Vital signs, including s ystolic and diastolic blood pressure (mmHg), pulse rate (beats per minute), 
body  temperature (°C), and respi[INVESTIGATOR_714352], baseline and every  
subsequent on -site visit. Height (cm) will be measured at Screening (Visit 1) only . Body  weight 
(kg) will be measured at Screening (Visit 1) and EOT/EOS visits. Refer to Section 1.[ADDRESS_972875] administration. A minimum of 3 complexes in an 
appropriate lead (lead II) will be averaged to determine the PR -interval, QT/QTc -interval, 
QRS -complex and heart rate will be measured f or each ECG. Refer to ECG reading manual for 
more details. All ECG recordings will be centrally read b y independent experts.
8.2.4 Clinical safety  laboratory  assessments
The clinical laboratory  tests are planned to be conducted at a central laboratory . 
See Appe ndix 2 ( Section 10.2) for the list of clinical laboratory  tests to be performed and to the 
SoA for the timing and frequency . 
The Investigator must review the laboratory  report, document this review, and record an y 
clinically  relevant changes occurring during the study  in the AE section of the CRF. The 
laboratory  reports must be filed with the source documents. 
Clinically  significant 
abnormal laboratory  findings are those which a re not associated with the underly ing 
disease, unless judged b y the I nvestigator to be more severe than expected for the 
participant's condition.
All laboratory  tests with values considered clinically  significantl y abnormal during 
participation in the stud y or within [ADDRESS_972876] dose of study  intervention should 
be repeated until the values return to normal or baseline or are no longer considered 
clinically  significant b y the Investigator or medical monitor.
If such values do not return to normal/baseline within a period of time judged reasonable 
by [CONTACT_737], the etiology  should be identified and the Sponsor notified.
All protocol -required laboratory  assessments, as defined in Appendix 2 ( Section 10.2), must be 
conducted in accordance with the laboratory  manual and the SoA.
If laboratory  values from non
-protocol specified laboratory  assessments performed at the 
institution’s local laboratory  require a change in participant mana gement or are considered 
clinically  significant b y the Investigator (eg, SAE or AE or dose modification), then the 
results must be recorded in the CRF.
The clinical laboratory  parameters that will be measured are described in Appendix 2: Clinical 
laboratory  tests ( Section 10.2). Decision trees for the management of certain laboratory  
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 54abnormalities by  [CONTACT_208551] 6: L iver and Other Safety : Suggested Actions 
and Follow -up Asse ssments ( Section 10.6).
For patient(s) who have consented to it, the samples that are archived, unused or left over after 
planned testing may  be used for additional research purposes (Appendix 17: Future Use of 
Samples, see Section 10.17 .
8.3 ADVERSE EVENTS AND SERIOUS A DVERSE EVENTS
The definitions of an AE or SAE can be found in Appendix 3: Adverse Events: Definitions and 
Procedures fo r Recording, Evaluating, Follow -up, and Reporting (Section
10.3).
AE will be reported b y the participant (or, when appropriate, b y a caregiver, surrogate, or the 
participant's legall y authorize
d representative). 
The Investigator and an y qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible for following 
up AEs that are serious, considered related to t he IMP or study  procedures, or that caused the 
participant to discontinue the I MP ( Section 7).
8.3.[ADDRESS_972877] (AESI
) is an AE (serious or nonserious) of scientific and 
medical concern specific to the Sponsor ’s product or program, for which ongoing monitoring and 
immediate notification by [CONTACT_714392] r equired. Such events may  require 
further investigation in order to characterize and understand them. Adverse events of special 
interest may  be added, modified or removed during a study  by [CONTACT_12548].
For these AESIs, the Sponsor will be informed im mediately  (ie, within 24 hours), per SAE 
notification described in Section 8.3.2, even if not fulfilling a seriousness criterion, using the 
corresponding pages in the CRF (to be sent) or screen s in the e -CRF.  If an SAE or any  AESI of 
anaph ylactic reactions or sy stemic allergic reactions that are related to IMP and require treatment, 
or severe injection site reactions lasting longer than 24 hours, occurs in a patient, blood samples 
should be col lected for determination of functional dupi[INVESTIGATOR_24762], and ADA 
assessment at or near the onset and completion of the occurrence of the event, if possible (see 
Section
[IP_ADDRESS] for details).
Clinically  symptomatic eosinophilia (or eosinophilia associated with clinical sy mptoms)
Anaph ylactic reactions or sy stemic allergic reactions that are related to IMP and require 
treatment (see Appendix 15, Section 10.15)
Severe injection site reactions that last longer than 24 hours
Any infection meeting at least one of the following criteria:
-Any serious infection (SAE)
-
Requires parenteral (intravenous, intramuscular, subcu taneous) antimicrobial therapy  
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 55-Requires oral antimicrobial therap y for longer than 2 weeks
-Is a parasitic infection 
- Is an opportunistic infection (see Appendix 16, Section 10.16)
Note:  antimicrobial therapy  refers to antibiotic, antiviral, and antifungal agents
Significant ALT elevation
-ALT >5 x the upper limit of normal (ULN) in patients with baseline ALT ≤[ADDRESS_972878]; 
or
-ALT >8 x UL N if baseline ALT >[ADDRESS_972879]
Pregnancy  of a female subject entered in a study  as well as pregnancy  occurring in a 
female partner of a male subject entered in a stu dy with I MP/NIMP; 
Pregnancy  occurring in a female patient entered in the clinical trial or in a female 
partner of a male patient entered in the clinical trial. I t will be qualified as an SAE 
only if it fulfills one of the seriousness criteria (see Appendi x 3 [Section 10.3]) .
In the event of pregnancy in a female participant, IMP should be discontinued. 
-Follow -up of the pregnancy  in a female participant or in a female partner of a male 
particip
ant is mandatory  until the outcome has been determined ( seeAppendix 4 
[Section 10.4])
-Abnormal pregnancy  outcomes (eg, spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ecto pic pregnancy ) are considered SAEs
Symptomatic overdose (serious or nonserious) with I MP/NIMP
An overdose (accidental or intentional) with the IMP is an event suspected by  [CONTACT_714393] b y the patient and defined as at least twice the 
intended dose during an interval of less than 8 days. The circumstances (ie, accidental or 
intentional) should be clearly  specified in the verbatim and sy mptoms, if any
, entered on 
separate adverse event forms.
An overdose (accidental or intentional) with an y NIMP is an event suspected by  [CONTACT_400725] b y the patient and defined as at least twice the 
maximum daily  dose as specified in a drug label, wi thin the intended therapeutic interval. 
"The circumstances (ie, accidental or intentional) should be clearl y specified in the 
overdose form". 
The definitions of an AE or SAE can be found in Appendix 3 ( Section 10.3).
Adverse event will be reported by [CONTACT_2299] (or, when appropriate, b y a caregiver, surrogate, 
or the participant's legally authorized representative). 
The Investigator and an y qualified designees are responsi ble for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible for following 
up AEs that are serious, considered related to the study  intervention or study  procedures, or that 
caused the participant to discontinue the study  (Section 7). 
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 568.3.2 Time period and frequency  for collecting A E and SA E information
All AEs and SAEs will be collected from the signing of the ICFuntil the follow -up visit at t he 
time points specified in the SoA ( Section 1.3), or up to recovery or stabilization of any  AE to be 
followed
-up as specified in this protocol, whichever comes last.
All SAEs and AESI  will be recorded and reported to the Sponsor or designee within 24 hours, as 
indicated in Appendix 3 ( Section
10.3). The Investigator will submit an y updated SAE data to the 
Sponsor wit hin 24 hours of it being available.
Investigators are not obligated to activel y seek AE or SAE after conclusion of the study
 
participation. However, if the Investigator learns of an y SAE, including a death, at an y time after 
a participant has been discharg ed from the study , and he/she considers the event to be reasonabl y 
related to the stud y intervention or study participation, the I nvestigator must promptly  notify  the 
Sponsor.
The method of recording, evaluating, and assessing causality  of AE and SAE and t he procedures 
for completing and transmitting SAE reports are provided in Appendix 3 ( Section 10.3).
8.3.3 Method of detecting A Es and SA Es
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open
-ended and 
non-leading verbal questioning of the participant is the preferred method to inquire about AE 
occurrences.
8.3.4 Follo w-up of A Es and SA Es
After the initial AE/SAE report, the Investigator is required to proactivel y follow each parti cipant 
at subsequent visits/contacts.  At the pre -specified study  end-date, all SAEs, and non- serious AEs 
of special interest (as defined in Section 8.3.1), will be followed until resolution, stabilization, the 
event is otherwise explained, or the participant is lost to follow -up (as defined in Section 7.3). 
Further information on follow -up procedures is given in Appendix 3 ( Section
10.3).
8.3.5 Regulatory  reporting requirements for SA Es
Prompt notification by  [CONTACT_46352] a SAE is essential so that legal 
obligations and ethical responsibilities towards the safet y of participants and the safet y of 
a study  intervention under clinical investigation are met. 
The Sponsor has a legal responsibility  to notify  both the local regulatory  authority  and 
other regulatory  agencies about the safet y of a study  interventio n under clinical 
investigation. The Sponsor will comply  with country -specific regulatory  requirements 
relating to safet y reporting to the regulatory  authority , Institutional Review Boards 
(IRB)/Independent Ethics Committees (I EC), and Investigators.
Invest igator safety  reports must be prepared for suspected unexpected serious adverse 
reactions (S[LOCATION_003]R) according to local regulatory  requirements and Sponsor policy  and 
forwarded to Investigators as necessary .
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 57An Investigator who receives an Investigator safety report describing a SAE or other 
specific safet y information (eg, summary or listing of SAEs) from the Sponsor will review 
and then file it along with the I nvestigator’s Brochure and will notify  the IRB/IEC, if 
appropriate according to local requirements .
8.3.6 Pregnancy
See AESI ( Section 8.3.1).
8.3.7 Adjudication Committee
Adjudication will be performed by  [CONTACT_714394], cardiovascular SAEs and respi
[INVESTIGATOR_714353] y endpoints. A 
confirmatory  adjudication will occur for AECOPD exacerbations.  Adjudicators will adjudicate 
these events in a consistent and unbiased manner throughout the stud y.
The goal of the adjudication is to ensure that all events reported b y the site are judged uniformly, 
using pre -specified criteria by  a group independent of the Sponsor.  Adjudication Committee 
members will be blinded to treatment allocation.  Adjudication Committee members’ 
responsibilitie s and the process for data review are described in the AC Charter/Manual of 
Operation.
8.3.8 Disease- related events and/or disease- related outcomes not qualify ing as A Es or 
SAEs
In this study, some AEs are considered related to the underl ying condition and thus will not be 
considered unexpected. Specificall y, for patients with COPD worsening of underlying condition is 
not considered an AE unless it meets serious criteria as defined in Appendix 3 (Section 10.3).
Any other AE not listed as an expected event in the IB or in this protocol will be considered 
unexpected.
8.3.[ADDRESS_972880] complaints / medical device incidents (including 
malfunctions)
Any defect in the IMP/NIMP must be reported as soon as possible by  [CONTACT_13150] a product complaint form within required timelines.
Appropriate information (eg, samples, labels or documents like pi[INVESTIGATOR_12989]) related to 
produc t identification and to the potential deficiencies may  need to be gathered. The Investigator
will assess whether or not the quality  issue has to be reported together with an AE or SAE.
8.4 TREATMENT OF OVERDOS E
Overdose is an AESI (defined in Section
8.3.1). No antidote is available for dupi[INVESTIGATOR_12458].
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 58In the event of an overdose, the Investigator/treating ph ysician should:
1.Contact [CONTACT_27465] .
2.Closely  monitor the participant for an y AE/SAE and laboratory  abnormalities until study  
intervention can no longer be detected s ystemically . 
3.Obtain a serum sample for PK anal ysis as soon as possible from the date of the last dose of 
study  intervention if requested by  [CONTACT_1689] (determ ined on a case -by-case 
basis).
4.Document the quantit y of the excess dose as well as the duration of the overdose in the 
CRF.
Decisions regarding dose interruptions or modifications will be made by  [CONTACT_714395].
8.5 PHA RMA COKINETICS
8.5.1 Systemic drug concentration and anti -drug antibodies
[IP_ADDRESS] Sampling time
Blood samples will be collected for determination of functional dupi[INVESTIGATOR_181159] -dupi[INVESTIGATOR_714354] ( Section 1.3). Special procedures for collection, 
storage, and shippi[INVESTIGATOR_714355]. The date and time 
of collection should be recorde d in the patient e -CRF.
[IP_ADDRESS] Handling procedures
Special procedures for collection, storage, and shippi[INVESTIGATOR_181207]. An overview of handling procedure for samples used in the determination of 
systemic drug concentration and ADA is provided in Table 6.
Table 6
-Summary of handling procedures for dupi[INVESTIGATOR_328696]-dupi[INVESTIGATOR_328697] 5mL 5 mL
Anticoagulant None None
Blood handling procedures See Operational Manual See Operational Manual
Serum aliquot split 2 aliquots 2 aliquots
Storage conditions <6 months:  below -20°C
<24 months: below -80°C (preferred)<6 months:  below -20°C
<24 months: below -80°C (preferred)
Serum shipment condition In dry ice In dry ice
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page [IP_ADDRESS] Bioanalytic method
Serum PK and ADA samples will be assay ed using validated methods as described in Table 7.
Table 7
-Summary of bioanalytical methods for dupi[INVESTIGATOR_181159] -dupi[INVESTIGATOR_714356]-dupi[INVESTIGATOR_714357]- chemiluminescence
Site of bioanalysis Regeneron Regener on
ELISA=enzyme -linked immunosorbent assay.
Drug concentration information that may  unblind the study  will not be reported to investigative 
sites or blinded personnel until the study  has been unblinded.
Note: If an SAE or an y AESI  of anaph ylactic reactio ns or sy stemic allergic reactions that are 
related to IMP and require treatment, or severe injection site reactions lasting longer than [ADDRESS_972881] be documented and approved by  [CONTACT_714396], but will not constitute a protocol amendment. The 
IRB/IEC will be informed of an y safet y issues that require al teration of the safet y monitoring 
scheme or amendment of the I CF.
8.6 PHA RMA CODYNA MICS
8.6.1 Pharmacody namic variables/biomarkers
Pharmacod ynamic response of selected biomarkers
-PARC
-Eotaxin -3
-FeNO (postbronchodilator) 
-Total IgE
-Fibrinogen
Serum/plasma for archival purposes
Induced sputum for RNA expression (optional for patients at a subset of sites).
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 60For timing of PD sample collection refer to SoA ( Section 1.3 )
Assay  methodologies are briefl y summari zed below. More detailed information on the collection, 
handling, transport, and preservation of samples (eg, minimum volumes required for blood 
collection and for aliquots for each biomarker assay) will be provided in a separate laboratory  
manual.
Specifi c procedures for collection, storage and shippi[INVESTIGATOR_714358] a lab manual.
Whole blood biomarkers
Blood eosinophil and neutrophil counts will be measured as part of the standard 5 -part WBC 
differential cell count on a hematology  auto 
analyzer. Blood eosinophil and neutrophil counts will 
be measured at timepoints additional to hematology  (Section 1.3).
Plasma/serum biomarkers
PARC will be assay ed using a validated enz yme immunoassay .
Fibrinogen assay : (development of immunoassay  method ongoing).
Eotaxin -3 will be measured in heparinized plasma with a validated enz yme immunoassay .
Total IgE will be measured with a quantitative method
(eg, Phadia ImmunoCAP) approved for 
diagnostic testing.
Exhaled nitric oxide
FeNO will be anal yzed using a NIOX instrument (Aerocrine AB, Solna, Sweden), or similar 
analyzer using a flow rate of 50 mL /s, and reported in parts per billion (ppb). This asses sment 
should be conducted prior to spi[INVESTIGATOR_714359] a fast of at least 1 hour. Further details on 
the procedure for measuring exhaled nitric oxide with NIOX will be provided in a separate 
instruction manual.
8.7 PHARMA COGENOMICS
Pharmacogenetic/Pharmac ogenomic testing is optional and voluntary . Written informed consent 
must be obtained before sampling.
For those patients who consent to the optional pharmacogenetic/pharmacogenomic sample 
collection section of the informed consent form (ICF), blood sample s for exploratory  genetic 
analysis of DNA or RNA will be collected at the study  visit as specified in the SoA ( Section 1.3), 
and these samples will be stored for future analy sis. Specific proce dures for collection, storage 
and shippi[INVESTIGATOR_208480]/pharmacogenomic samples will be provided in a lab manual. 
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 61For patient(s) who have consented to it, the samples that are archived, unused or left over after 
planned testing may  be used for addit ional research purposes (Appendix 17: Future use of 
samples, see Section 10.17 ).
In the event of DNA extraction failure, a replacement genetic blood sample may  be requested 
from the participant.
8.8 BIOMA RKERS
Pharmacod ynamic and pharmacogenetics biomarkers are described in Section 8.6.1 and 
Section 8.7, respectivel y .
8.9 HEALTH CARE RESOURCE UTILIZ ATION
A questionnaire of health care resource utilization (reliever medication, physician visit, 
hospi[INVESTIGATOR_059], emergency  or urgent medical care facility  visit, sick leaves including loss of usual 
activity  days) will be collected b y the investigator for all participants throughout the study.
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: [ADDRESS_972882] placebo on reducing the 
annualized rate of moderate- to-severe COPD exacerbations over the 52 -week treatment period are 
as follows:
Null hy pothesis: 
Alternative h ypothesis: 
Where and represent exacerbation rate in the dupi[INVESTIGATOR_197356], 
respectivel y.
The statistical hy potheses used to test dupi[INVESTIGATOR_12458] [ADDRESS_972883] placebo on improving pre -
bronchodilator FEV1 from baseline to Week 12 are as follows:
Null hy pothesis: 
Alternative h ypothesis: 
Where and represent change in pre -bronchodilator FEV 1in the dupi[INVESTIGATOR_208481], respectively .
The statistical hy potheses to be tested on the key  secondary  endpoints, change in 
pre-bronchodilator FEV 1from baseline to Week 52 and change from baseline to Week 52 in the 
SGRQ total score compared to placebo, can be specified similarl y as those on the change in FEV 1 
at Week 12. For the proportion of patients with SGRQ improvement ≥4 points at Week 52, the 
null hy pothesis is the odds ratio of response between the dupi[INVESTIGATOR_714360] 
1, while the alternative hypothesis is the odds ratio is unequal to 1.
9.2 SAMPLE SIZE DETERMIN ATION
The sample size of the study  is determined based on power calculations for the primary  endpoints.
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 63For the endpoint of annualized rate of moderate or severe COPD exacerbations over the 52 -week 
treatment period, assuming the number of exacerbations following a negative binomial 
distribution with a dispersion parameter of 1, a placebo annualized rate of  exacerbations being 
1.5, an average treatment duration of 0.95 year (to account for an average of 5% of the planned 
treatment period with missing data), and a r andomization ratio of 1:1 to the two treatment arms, 
with 924 randomized patients (462 for each treatment arm), the study  will have 90% power to 
detect a 25% relative risk reduction (ie, annualized rate of 1.125 for the dupi[INVESTIGATOR_24769]) in the 
annualized r ate of moderate or severe COPD exacerbations at the 2
-tailed significance level of 
α=0.049 ( an administrative penalt y of 0.001 will be taken from the significance level used at final 
analysis due to a planned interim analy sis; details are provided in Section 9.5). For the endpoint of 
change from baseline in FEV 1at Week 12, the study  will have 99% power to detect a 0.1L 
improvement at the significance level of α=0.049, assuming a common standard deviation of 0.35 
and 5% of patients with missing data.
Patients will be randomized using a 1:1 randomization ratio to dupi[INVESTIGATOR_12458] 300 mg q2w or placebo. 
Randomization will be stratified b y countr y and asthma history  (Yes or No). 
9.3 POPULA TIONS FOR ANA LYSES
For purposes of analy sis, the following populations are defined ( Table 8):
Table [ADDRESS_972884] 
randomization will be used in any analysis population. The safety experien ce 
associated with any later randomization will be assessed separately.
Intent- to-treat (ITT) All randomized patients analyzed according to the treatment group allocated by 
[CONTACT_714397] a dose of the IMP, analyzed according to the treatment actually received.
Randomized patients for whom it is unclear whether they took the study medication 
will be included in the safety po pulation as randomized. 
For patients on dupi[INVESTIGATOR_714361], the actual treatment group allocation for as -treated analysis will be the 
dupi[INVESTIGATOR_24769].
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 64The pharmacodynamic (PD) analyses will be performed on the safety population.
Pharmacokinetic (PK) The PK population includes all patients in the safety population with at least one non -
missing result for functional dupi[INVESTIGATOR_714362]. Patients will be analyzed according to the treatment actually received.
Antidrug antibody (ADA) ADA population includes all patients in the safety population who have at least one non -
missing ADA result (either ‘ADA negative’ or ‘ADA positive’) after first dose of the st udy 
treatment.  Patients will be analyzed according to the treatment actually received.
9.4 STATISTICA L ANAL YSES
The statistical anal ysis plan will be developed and finalized before database lock and will describe 
the participant populations to be included in the analy ses, and procedures for accounting for 
missing, unused, and spurious data. This section is a summary  of the planned statistical analy ses 
of the primary  and secondary  endpoints.
9.4.1 Efficacy  analy ses
Table 9
-Efficacy analyse s
Endpoint Statistical A nalysis Methods
Primary
Annualized rate of 
moderate and 
severe COPD 
exacerbations over 
52 week treatment 
periodThe annualized rate of moderate and severe COPD exacerbation events will be analyzed using a negative 
binomial regressi on model. The model will include the total number of events occurring during the 52 -week 
treatment period as the response variable, with the treatment group, region (pooled country), asthma history 
(Yes or No), smoking status at screening (current smokers or not), baseline disease severity (as % 
predicted post -bronchodilator FEV 1), and number of moderate or severe COPD exacerbation events within 
one year prior to the study ( ≤2, 3, or ≥4) as covariates. Log -transformed observation duration will be used 
as of fset variable. The estimated annualized event rate for each treatment group and its two -sided 95% 
confidence intervals will be derived. The event rate ratio of the dupi[INVESTIGATOR_208484], its two -
sided 95% confidence interval and p -value will be p rovided. Patients who permanently discontinue the study 
treatment will be encouraged to complete the study as planned and the additional off -treatment 
exacerbation events up to Week [ADDRESS_972885] model 
with repeated measures (MMRM). The model will include change from baseline in FEV 1values up to 
Week 12 as response variables, and factors for treatment group, age, sex, baseline height, region (pooled 
country), asthma history (Yes or No), smoking status at screening (current smokers or not), visit, treatment -
by-visit interaction, baseline pre -bronchodilator FEV 1, and FEV 1baseline -by-visit interaction as covariates. 
An unstructured correlation matrix will be used to model the within -patient err ors. Parameters will be 
estimated using restricted maximum likelihood method using the Newton -Raphson algorithm. The least 
square (LS) mean of the change in pre -bronchodilator FEV 1of each treatment group, difference in the LS 
mean changes between the dupi [INVESTIGATOR_125316], the corresponding 95% CI of the differences 
and p -values will be provided. For patients who discontinued the study treatment, off -treatment FEV 1values 
will be included in the analysis. Sensitivity analyses for handling missing dat a may include pattern mixture 
model by [CONTACT_714398][INVESTIGATOR_208412].
Subgroup analysis
To assess the consistency in treatment effects across different subgroup levels, subgroup analyses will be 
performed for the primary efficacy endpoints with respect to age, gender, region, race, weight, BMI, 
smoking status, disease severity (as % predicted post -bronchodilator FEV 1), number of moderate -or-severe 
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: [ADDRESS_972886] as change in 
pre-bronchodilator FEV 1at Week 52 except that the MMRM model will include the following covariates: 
treatment group, region (pooled country), asthma history (Yes or No), smoking status at screening (current 
smokers or not), visit, treatment -by-visit interaction, baseline SGRQ total score, and SGRQ baseline -by-visit 
interaction.
Proportion of 
patients with 
SGRQ 
improvement ≥ 4 
points at Week 52The proportion of patients with SGRQ improvement ≥4 points at Week 52 will be analyzed using a logistic 
regression model. The model will include treatment group, region (pooled country), asthm a history (Yes or 
No), smoking status at screening (current smokers or not), and baseline SGRQ total score as covariates. 
Patients with missing SGRQ total score at Week 52 will be considered as non -responders.
Other secondary
Change in pre -
bronchodilator
FEV 1from baseline 
to Weeks other 
than 12 & 52The change in pre -bronchodilator FEV 1from baseline at other time points will be analyzed in the same way 
as the change from baseline in pre -bronchodilator FEV 1at Week 52.
Change in 
post- bronchodilator 
FEV1, change in 
forced expi[INVESTIGATOR_17175] (FEF) 25- 75%The change in the spi[INVESTIGATOR_714363] -
bronchodilator FEV1 except that the corresponding baseline of the parameter will replace baseline pr e-
bronchodilator FEV 1to be adjusted for in the MMRM model.
Time to first 
moderate or severe 
COPD 
exacerbation 
compared to 
placebo during the 
52-week treatment 
periodThe time to first moderate or severe COPD exacerbation will be analyzed using a Cox regr ession model. 
The model will include the time to the first event as the dependent variable, and treatment group, region 
(pooled country), asthma history (Yes or No), smoking status at screening (current smokers or not), 
baseline disease severity (as % pred icted post -bronchodilator FEV1), and number of moderate or severe 
COPD exacerbation events within one year prior to the study ( ≤2, 3, or ≥4) as covariates. The Kaplan -
Meier method will be used to derive the probabilities that a patient would experience event up to specific 
timepoints for each treatment group.
Annualized rate of 
severe COPD 
exacerbations over 
the [ADDRESS_972887] as the primary 
analysis for the annualized rate of moderate or severe COPD exacerbation events.
Exploratory Analysis of Exploratory endpoints will be described in the SAP finalized before database lock.
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page [IP_ADDRESS] Multiplicity considerations
Multiplicity  is considered for testing multiple endpoints. The overall ty pe-I error rate will be 
controlled at the two -sided 0.05 level. 
An IA is planned in this study  (details are provided in Section 9.5), and an administrative penalty  
of 0.001 will be taken from the significance level used at final analysis and thus two -
sided 0.049 
will be used. A se quential testing procedure will be used for testing the two primary  endpoints in 
the following order:
E 01. Annualized rate of moderate and severe COPD exacerbations over [ADDRESS_972888] available 
value before randomization. The treatment emergent adverse event (TEAE) period is defined as 
the time between the first administration of study  medication to the last administration o f the I MP 
+ 98 day s.
Table 10-Safety analyses
Endpoint Statistical A nalysis Methods
AE, SAE, AE 
leading to death, 
AE leading to  
permanent 
treatment 
discontinuationAdverse event incidence tables will present by [CONTACT_714399] s (SOC) (sorted by [CONTACT_208562]), high -level group term (HLGT), high level term (HLT) and preferred term (PT) sorted in alphabetical 
order for each treatment group, the number (n) and percentage (% ) of patients experiencing an AE. Multiple 
occurrences of the same event in the same patient will be counted only once in the tables within a 
treatment phase. The denominator for computation of percentages is the safety population within each 
treatment group.
Proportion of patients with at least o ne TEAE, treatment emergent SAE, TEAE leading to death, and TEAE 
leading to permanent treatment discontinuation will be tabulated by [CONTACT_1570]. In addition TEAEs will 
be described according to maximum intensity and relation to the study drug. AEs tha t occur outside the 
treatment- emergent period will be summarized separately.
Major 
Cardiovascular 
Adverse Events  
(MACE)The number and percentage (% ) of patients with any treatment -emergent event selected for adjudication 
will be summarized by [CONTACT_303444] C and PT.
All events submitted for adjudication will be listed, including the final adjudicated result.
The number and percentage (% ) of patients experiencing a treatment -emergent adjudicated event will be 
summarize d within each treatment group.
Therisk d ifference (asymptotic 95% CI with continuity correction) will be computed for the dupi[INVESTIGATOR_208486]. Kaplan -Meier plots to depi[INVESTIGATOR_714364]
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 67Endpoint Statistical A nalysis Methods
AESI and other AE 
groupi[INVESTIGATOR_714365] d other AE groupi[INVESTIGATOR_714366]. For each type 
of AESI, the following analysis will be generated .
- A summary of the number (%) of patients with
• any TEAE
• any SAE (regardless of treatment -emergent status)
• any treatment- emergent SAE
• any AE leading to death
• any TEAE leading to death
• any TEAE leading permanent treatment discontinuation
• any TEAE related to IMP reported by [CONTACT_1697]
• Number of patients with the TEAE per 100 patient- years
• any TEAE by [CONTACT_11196], corrective treatmen t, and final outcome
- Kaplan -Meier (K -M) estimates of probability of having at least one TEAE at specific time points, 
and K -M curve to depi[INVESTIGATOR_208488]. 
The method to identify AESIs and other AE groupi[INVESTIGATOR_208489].
Death The following deaths summaries will be generated:
- Number (% ) of patients who died by [CONTACT_6960] (TEAE, on -study) summarized on the safety 
population by [CONTACT_82153] 
- Death in nonrandomized patients or randomized and not treated patient s
Treatment -emergent AE leading to death (death as an outcome on the AE eCRF page as reported by [CONTACT_3786]) by [CONTACT_148274], HLGT, HLT, and PT showing number (% ) of patients sorted by [CONTACT_208564], HLT, and PT.
Laboratory 
parametersResults and change from baseline for the parameters will be summarized by [CONTACT_209497], endpoint, minimum and maximum value. Summary statistics will include 
number of patients, mean, standard deviation, median, Q1, Q3, minimum, and maximum.
The following definitions will be applied to laboratory parameters.
- The potentially clinically significant abnormality (PCSA) values are defined as abnormal values 
considered medically important by [CONTACT_181295]/thresholds based on 
literature review and defined by [CONTACT_209498].
- PCSA criteria will determine which patients had at least [ADDRESS_972889] to the baseline status will be 
provided.
9.4.3 Other analy ses
PK, pharmacod ynamic, and biomarker exploratory anal yses will be described in the statistical 
analysis plan finalized before database lock. The population PK analy sis and pharmacod ynamic 
analyses will be presented separately  from the mai n clinical study  report (CSR).
Table 11provides a summary  of the planned statistical anal yses of the other endpoints.
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 68Table 11-Other analyses
Endpoint Statistical A nalysis Methods
PKSerum concentrations of SAR231893 (REGN668) will be summarized for the dupi[INVESTIGATOR_12458] t reatment group 
using arithmetic and geometric means, SD, standard error of the mean (SEM), coefficient of variation (CV), 
minimum, median and maximum per sampling time.
ADA The incidence of positive ADA response for SAR231893 (REGN668) will be provided by [CONTACT_6660]. 
The neutralizing antibody status will be summarized and the association of ADA with PK, efficacy and 
safety variables may be explored. The ADA analysis will be detailed in the SAP.
PD For all PD parameters, raw data at each visit, absolute changes from baseline, and percent changes from 
baseline will be summarized in descriptive statistics by [CONTACT_11571]. 
Summary plots (mean ± standard error of the mean) on raw data, absolute changes from baseline and 
percent changes from baseline will be provided by [CONTACT_6660].
9.[ADDRESS_972890] of 
the study  (patients, Investigators, Study  Team, and Pro ject Team) will have no access to the IA 
results.
At the IA, the efficacy  endpoints will be analy zed using the same methods described in the 
efficacy  anal yses section ( Section 9.4.1). The analy sis population for the IA wil l be the first 408 
patients randomized.  The anal ysis of the endpoints will use all the data collected for the analy sis 
population up to the I A cutoff time. An administrative penalty  of 0.001 will be taken from the 
significance level used at final anal ysis(i.e., two
-sided 0.049 will be used for the final analy sis).
The database lock for final anal ysis is planned based on the date when the last patient completes 
the Week [ADDRESS_972891] visit will be 
summariz ed in a CSR addendum.
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 6910 SUPPORTING DOCUMENTA TION AND OPERA TION AL 
CONSIDERA TIONS
10.1 APPENDIX 1: REGULA TORY, ETHICA L, AND STU DY OVERSIGHT 
CONSIDERA TIONS
10.1.1 Regulatory  and Ethical Considerations
This study  will be conducted in accordance with the protocol and with the following:
- Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and the applicable amendments and Council for International 
Organizations of Medical Sciences (CIOMS) International Ethical Guidelines
-Applicable ICH Good Clinical Practice (GCP) Guidelines
-Applicable laws and regulations
The protocol, protocol amendments, I CF, Investigator Brochure, and other relevant 
documents (eg, advertisements) must be submitted to an I RB/IEC by  [CONTACT_125485]/IEC before the study  is initia ted.
Any amendments to the protocol will require IRB/I EC approval before implementation of 
changes made to the study design, except for changes necessary  to eliminate an immediate 
hazard to study  participants.
The Investigator will be responsible for the f ollowing:
-Providing written summaries of the status of the study  to the IRB/IEC annually  or 
more frequently  in accordance with the requirements, policies, and procedures 
established by  [CONTACT_1201]/IEC
-Notify ing the IRB/IEC of SAEs or other significant safet y findings as required by  
[CONTACT_1744]/IEC procedures
-Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 536/2014 
for clinical studies (if applicable), and all other app licable local regulations .
10.1.2 Informed c onsent process
The Investigator or his/her representative will explain the nature of the study  to the 
participant or his/her legally  authorized representative and answer all questions regarding 
the study . 
Participants must be informed that their participation is voluntary . Participants will be 
required to sign a statement of informed consent that meets the requirements of [ADDRESS_972892] 
(HIPAA) requirements, where applicable, and the I RB/IEC or study  center. 
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 70The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study  and the date the written consent was 
obtained. The authorized person obtaining the informed consent must also sign the ICF.
Participants must be re -consented to the most current version of the ICF(s) during their 
participation in the study . 
A cop y of the ICF(s) must be provided to the participant or the participant’s legall y 
authorized representative. 
10.1.3 Data p rotection
Participants will be assigned a unique identifier by  [CONTACT_1034] . Any participant records or 
datasets that are transferred to the Sponsor will contain the identifier only ; participant 
names or an y information which would make the participant identi fiable will not be 
transferred.
The participant must be informed that his/her personal study -related data will be used by  
[CONTACT_9324]. The level of di sclosure must also 
be explained to the participant.
The participant must be informed that his/her medical records may  be examined by  
[CONTACT_159882] , by [CONTACT_6667]/IEC members, and by
 [CONTACT_90742].
10.1.4 Committees structure
Study committees
The study  data will be reviewed by  a DMC and adjudication committee.
[IP_ADDRESS] Data Monitoring Committee (DMC)
A DMC, independent from sponsor will be established for this study . This committee is 
comprised of externall y-based individuals with expertise in the diseases under study, biostatistics, 
or clinical research. The primary  responsibilities of the DMC are to review and evaluate the safety  
data during the course of the trial, r eview IA results and make appropriate recommendations 
regarding the conduct of the clinical trial to the Sponsor.
The DMC procedures and safet y data to be reviewed b y the DMC are described in the DMC 
charter. In the above capacities, the DMC is advisory  tothe Sponsor. The Sponsor is responsible 
for promptly  reviewing and for taking into account in a timely  manner the recommendations of 
the DMC in terms of trial continuation with or without alterations or of potential trial termination.
[IP_ADDRESS] Adjudication committ ee
Adjudication will be performed by  [CONTACT_714394], cardiovascular SAEs and respi[INVESTIGATOR_714353] y endpoints. A 
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 71confirmatory  adjudication will occur for AECOPD exacerbations. Adjudicators will adjudicate 
these events in a consistent and unbiased manner throughout the stud y.
The goal of the adjudication is to ensure that all events reported b y the site are judged uniformly, 
using pre -specified criteria by  a group independent of the Sponsor.  Adjudication Committee 
members will be blinded to treatment allocation.  Adjudication Committee members’ 
responsibilities and the process for data review are described in the AC Charter/Manual of 
Operation.
10.1.5 Dissemination of clinical study  data
[COMPANY_011] shares information about clinical trials and results on publically  accessible websites, based 
on compan y commitments, international and local legal and regulatory requirements, and other 
clinical trial disclosure commitments established by  [CONTACT_400744]. These 
websites include clinicaltrials.gov, EU clinicaltrialregister (eu.ctr), and sanofi.com, as well as 
some national registries.
In addition, results from clinical trials in patients are required to be submitted to peer -reviewed 
journals following internal compan y review for accuracy, fair balance and intellectual propert y. 
For those journals that request sharing of the analy zable data sets that are reported in the 
publication, interested researchers are directed to submit their request to 
clinicalstudy datarequest.com.
Individual participant data and supporting clinical documents are available for request at 
clinicalstudy datarequest.com. While making information available we continue to protect the 
privacy  of participants i n our clinical trials. Details on data sharing criteria and process for 
requesting access can be found at this web address: clinicalstudy datarequest.com .
10.1.6 Data quality  assurance
All participant data relating to the study will be recorded on printed or elect ronic CRF 
unless transmitted to the Sponsor or designee electronically  (eg, laboratory  data). The 
Investigator is responsible for verify ing that data entries are accurate and correct by  
[CONTACT_55896] y or el ectronically  signing the CRF.
The Investigator must ma intain accurate documentation (source data) that supports the 
information entered in the CRF.
The Investigator must permit study -
related monitoring, audits, IRB/IEC review, and 
regulatory  agency  inspections and provide direct a ccess to source data document s.
The Sponsor or designee is responsible for the data management of this study  including 
quality  checking of the data. 
Study  monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by  [CONTACT_1191], complete, and verifiable from 
source documents; that the safet y and rights of participants are being protected; and that 
the study  is being conducted in accordance with the currently  approved protocol and any  
other study  agreements, ICH GCP, and all appl icable regulatory  requirements.
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 72Records and documents, including signed ICFs, pertaining to the conduct of this study  
must be retained b y the Investigator for 15 years after study  completion unless local 
regulations or institutional policies requi re a longer retention period. No records may  be 
destroy ed during the retention period without the written approval of the Sponsor. No 
records may  be transferred to another location or party  without written notification to the 
Sponsor. 
10.1.7 Source documents
Source documents provide evidence for the existence of the participant and substantiate 
the integrit y of the data collected. Source documents are filed at the Investigator ’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from sourc e 
documents must be consistent with the source documents or the discrepancies must be 
explained. The Investigator may need to request previous medical records or transfer 
records, depending on the study . Also, current medical records must be available.
Definition of what constitutes source data can be found in the Study  Reference Manual.
10.1.[ADDRESS_972893] been collected and a study -site closure visit has been performed.
The Investigator may initiate study -site closur e at any  time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.
Reasons for the earl y closure of a stud y site b y the Sponsor or Investigator may include but are 
not limited to:
Failure of the Investi gator to comply  with the protocol, the requirements of the IRB/IEC or 
local health authorities, the Sponsor 's procedures, or GCP guidelines
Inadequate recruitment of participants by  [CONTACT_737]
Discontinuation of further study  intervention development
10.1.9 Publication p olicy
The results of this study  may  be published or presented at scientific meetings. If this is 
foreseen, the Investigator agrees to submit all manuscripts or abstracts to the Sponsor
before submission. This allows the Sponsor to protect pro prietary  information and to 
provide comments.
The Sponsor will comply with the requirements for publication of study  results. I n 
accordance with standard editorial and ethical practice, the Sponsor will generall y support 
publication of multicenter studies only in their entirety  and not as individual site data. In 
this case, a coordinating Investigator [INVESTIGATOR_327426].
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 73Authorship will be determined by  [CONTACT_11403] I nternational 
Committee of Medical Journal Editors authorship requirements.
10.2 APPENDIX 2: CLINICAL LA BORA TORY TESTS
The tests detailed in Table 12will be performed by  [CONTACT_2237] . 
Local laboratory  results are only  required in the event that the central l aboratory  results are 
not available in time for either study  intervention administration and/or response 
evaluation. If a local sample is required, it is important that the sample for central anal ysis 
is obtained at the same time. Additionally , if the loca l laboratory  results are used to make 
either a stud y intervention decision or response evaluation, the results must be entered into 
the CRF.
Protocol -specific requirements for inclusion or exclusion of participants are detailed in 
Section 5 of the protocol.
Additional tests may  be performed at an y time during the stud y as determined necessary 
by [CONTACT_400745].
Table 12-Protocol -required safety laboratory assessments
Laboratory 
assessmentsParameters
Hematology To include hemoglobin, hematocrit, platelet count, total white blood cell count with five -part 
differential count, differential count, and total red blood cell c ount
Clinical chemistry To include creatinine, blood urea nitrogen, glucose, uric acid, total cholesterol, total protein, 
albumin, total bilirubin (in case of values above the normal range, differentiation in conjugated and 
non-conjugated bilirubin), alan ine aminotransferase (ALT), aspartate aminotransferase (AST), 
alkaline phosphatase, lactate dehydrogenase, electrolytes (sodium, potassium, chloride), 
bicarbonate, and creatine phosphokinase.
Routine urinalysis To include urine dipstick analysis including specific gravity, pH, glucose, ketones, blood, protein, 
nitrite, leukocyte esterase, urobilinogen and bilirubin (by [CONTACT_5230]).  If any assessment on the dipstick 
is abnormal, a urine sample should be sent to the central laboratory for testing. If po sitive for 
proteins, microscopic analysis is performed by [CONTACT_12115].
Other tests Clinical laboratory testing at Screening Visit 1 will include hepatitis screen covering hepatitis B 
surface antigen (HBs Ag), hepatitis B surface antibody (HBs Ab), hepatitis B core antibody (HBc 
Ab), hepatitis C virus antibodies (HCV Ab), Human Immunodeficiency Virus (HIV) screen 
(Anti-HIV-1 and HIV -2 antibodies) and anti -nuclear antibody (ANA). In case of results showing HBs 
Ag (negative), HBs Ab (negative) and HBc Ab (positive), an HBV DNA testing may be performed 
prior to randomization to rule out a false positivity if the Investigator believes the patient is a false 
positive, or to clarify the serological status if the Investigator finds it unclear to interpret in absence 
of known HBV infection. In case of results showing HCV Ab (positive), an HCV RNA testing may be 
performed to rule out a false positivity, if the Investigator believes the patient is a false positive. 
Note: Anti -ds DNA antibody will be tested if AN A is positive ( ≥1:160 titer).
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: [ADDRESS_972894] document their review of each laboratory  safet y report.
Laboratory /anal yte results that could unblind the study  will not be reported to investigative sites 
or other blinded personnel until the study  has b een unblinded .
10.3 APPENDIX 3: ADVERSE EVENTS: DEFI NITIONS A ND PROCEDUR ES FOR 
RECORDING, EVA LUATING, FOLLOW -UP, A ND REPORTING
DEFINITION OF AE
AE definition
An AE is an y untoward medical occurrence in a patient or clinical study participant, 
temporally associa ted with the use of study  intervention , whether or not considered related 
to the study  intervention .
NOTE: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) tempo rally 
associated with the use of study  intervention .
Events 
meeting the AE definition
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) or 
other safet y assessments (eg, ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, considered clinicall y significant in the medical 
and scientific judgment of the Investigator (ie, not related to progression of underly ing 
disease).
Exacerbation of a chronic or intermittent pre- existing condition including either an 
increase in frequency  and/or intensity  of the condition.
New conditions detected or diagnosed after stud y intervention administration even though 
it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug- drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication.
"Lack of efficacy " or "failure of expected pharmacological action" per se will not be
reported as an AE or SAE. Such instances will be captured in the efficacy  assessments. 
However, the signs, s ymptoms, and/or clinical sequelae resulting from lack of efficacy  
will be reported as AE or SAE if they fulfil the definition of an AE or SAE. 
Thesigns, s ymptoms, and/or clinical sequelae resulting from lack of efficacy  will be 
reported as AE or SAE if they  fulfil the definition of an AE or SAE. Also, "lack of 
efficacy " or "failure of expected pharmacological action" also constitutes an AE or SAE.
Events NOT meeting the AE definition
AECOPD unless it meets the criteria for SAE.
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 75Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judged by  [CONTACT_714400]’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of the 
disease/disorder being studied, unless more severe than expected for the participant’s 
condition.
Medi cal or surgical procedure (eg, endoscop y, appendectom y): the condition that leads to 
the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluct uations of pre -existing disease(s) or condition(s) present or 
detected at the start of the study  that do not worsen.
DEFINITION OF SAE
If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions 
are met (eg, hospi[INVESTIGATOR_1080]/s ymptoms of the disease under study , death due to 
progression of disease).
A SAE is defined as any untoward medical occurrence that, at any dose:
a)Results in death
b)Is life -threatening
The term 'life -threatening' in the definition of 'seriou s' refers to an event in which the 
participant was at risk of death at the time of the event. I t does not refer to an event, which 
hypothetically  might have caused death, if it were more severe.
c)Requires inpatient hospi[INVESTIGATOR_63995] g hospi[INVESTIGATOR_177257], hospi[INVESTIGATOR_19949] (usually 
involving at least an overnight stay ) at the hospi[INVESTIGATOR_19950]/or treatment that would not have been appropriate in the ph ysician’s office or 
outpatient setting. Complications that occur during hospi[INVESTIGATOR_1084]. If a 
complication prolongs hospi[INVESTIGATOR_9236], the event is 
serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was necessary , the AE 
should be considered serious.
Hospi[INVESTIGATOR_5187] a pre-existing condition that did not worsen from 
baseline is not considered an AE.
d)Results in persistent disability/incapacity
The term disability  means a sub stantial disruption of a person’s ability  to conduct normal 
life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and 
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 76accidenta l trauma (eg, sprained ankle) which may  interfere with or prevent every day life 
functions but do not constitute a substantial disruption.
e)Is a congenital anomaly/birth defect
f)Other situations:
Medical or scientific judgment should be exercised in deciding whether SAE reporting is 
appropriate in other situations such as important medical events that may  not be 
immediately  life-threatening or result in death or hospi[INVESTIGATOR_160340]. These events should usually  be considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency  room or at home for allergic bronchos pasm, blood dy scrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency  
or drug abuse.
RECORDING AND FOLLOW -UP OF AE AND/OR SAE
AE and SAE recording
When an AE/SAE occurs, it is the responsibility  of the I nvestigator to review all
documentation (eg, hospi[INVESTIGATOR_1088], laboratory  reports, and diagnostics reports) 
related to the event.
The Investigator will then record all relevant AE/SAE information in the CRF.
It is notacceptable for the Investigator to send photocopi[INVESTIGATOR_10914]’s medical 
records to the Sponsor’s representative in lieu of completion of the AE/SAE CRF page.
There may  be instances when copi[INVESTIGATOR_714367]’s representative. I n this case, all participant identifiers, with the exception of 
the participant number, will be redacted on the copi[INVESTIGATOR_12997]’s representative.
The Investigator will attempt to establish a diagnosis of the event based o n signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the 
individual signs/sy mptoms) will be documented as the AE/SAE.
Assessment of intensity
The Investigator will make an assessment of intensity  for each AE and SAE r eported during the 
study  and assign it to 1 of the following categories:
Mild: An event that is easily  tolerated by  [CONTACT_2299], causing minimal discomfort and 
not interfering with every day activities.
Moderate: An event that causes sufficient discomfo rt and interferes with normal every day 
activities.
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 77Severe: An event that prevents normal every day activities. An AE that is assessed as 
severe should not be confused with a SAE. Severe is a category  utilized for rating the 
intensity  of an event; and both A Es and SAEs can be assessed as severe.
An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes as described 
in the definition of an SAE, NOT when it is rated as severe.
Assessment of causality
The Investigator is obligated to a ssess the relationship between stud y intervention and 
each occurrence of each AE/SAE.
A "reasonable possibility " of a relationship conveys that there are facts, evidence, and/or 
arguments to suggest a causal relationship, rather than a relationship cannot be ruled out.
The Investigator will use clinical judgment to determine the relationship.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other risk 
factors, as well as the temporal relationship of the event to study  intervention
administration will be considered and investigated.
The Investigator will also consult the Investigator’s Brochure (IB) and/or Product 
Information, for marketed products, in his/her assessment.
For each AE/SAE, the Investigator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causalit y.
There may  be situations in which an SAE has occurred and the Investigator has minimal 
information to include in the initial report to the Sponsor’s representative. How ever, it is 
very important that the Investigator always make an assessment of causality for 
every event before the initial transmission of the SAE data to the Sponsor’s 
representative.
The Investigator may  change his/her opi[INVESTIGATOR_714368]-up information 
and send a SAE follow -up report with the updated causality  assessment.
The causality  assessment is one of the criteria used when determining regulatory  reporting 
requirements.
Follow -up of AEs and SAEs
The Investigator is obligated to p erform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically  indicated or as requested by  [CONTACT_1034]’s 
representative to elucidate the nature and/or causality  of the AE or SAE as fully  as 
possible. This may  include additi onal laboratory  tests or investigations, histopathological 
examinations, or consultation with other health care professionals.
New or updated information will be recorded in the originally  completed CRF.
The Investigator will submit any  updated SAE data to the Sponsor/Sponsor’s representative 
within 24 hours of receipt of the information.
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 78REPORTING OF SAES
SAE reporting to the Sponsor’s representative via an electronic data collection tool
The primary  mechanism for reporting an SAE to the Sponsor’s represen tative will be the 
electronic data collection tool.
If the electronic s ystem is unavailable for more than 24 hours, then the site will use the 
paper SAE data collection tool (see next section).
The site will enter the SAE data into the electronic sy stem as soon as it becomes available.
After the stud y is completed at a given site, the electronic data collection tool will be taken 
off-line to prevent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE from a study  participant or receives updated data 
on a previousl y reported SAE after the electronic data collection tool has been taken off -
line, then the site can report this information on a paper SAE form (see next section) or to 
the Sponsor’s representative by  [CONTACT_97535] e.
Contacts for SAE reporting can be found in the Protocol.
SAE reporting via paper CRF (if eCRF is not available)
Facsimile transmission of the SAE paper CRF is the preferred method to transmit this 
information to the Sponsor.
In rare circumstances and in the absence of facsimile equipment, notification by [CONTACT_13186] a cop y of the SAE data collection tool sent by [CONTACT_13187].
Initial notification via telephone does not replace the need for the Investigator to complet e 
and sign the SAE CRF pages within the designated reporting time frames.
Contacts for SAE reporting can be found in the Protocol.
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 7910.4 APPENDIX 4: CONTRACEPTIVE GUIDA NCE AND COLLECTION OF PREGNA NCY 
INFORMA TION
DEFINITIONS:
Woman of childbearing potential (WOC BP)
A woman is considered fertile following menarche and until becoming post -menopausal unless 
permanentl y sterile (see below).
Women in the following categories are not considered WOCBP
1.Premenarchal
2.Premenopausal female with 1 of the following:
-Documented hysterectomy
-Documented bilateral salpi[INVESTIGATOR_1656]
-Documented bilateral oophorectom y
Note:  Documentation can come from the site personnel’s: review of the participant’s 
medical records, medical examination, or medical history  interview.
3.Postmenopausal femal e
- A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal 
range may  be used to confirm a postmenopausal state in women not using hormonal 
contr aception or hormonal replacement therapy  (HRT). However, in the absence of 
12months of amenorrhea, a single FSH measurement is insufficient. 
- Females on HRT and whose menopausal status is in doubt will be required to use one 
of the non- estrogen hormonal highl y effective contraception methods if they wish to 
continue their HRT during the stud y. Otherwise, they must discontinue HRT to allow 
confirmation of postmenopausal status before study  enrollment.
Female participants of childbearing potential are eligib le to participate if they  agree to use a 
highl y effective method of contraception consistently and correctly as described in Table 13.
Table 13-Highly effective contraceptive methods
Highl y effective contraceptive methods that are user dependenta
Failure rate of <1% per year when used consistently and correctly.
Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation
 Oral 
 Intravaginal 
 Transdermal
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 80Progestogen only hormonal contraception associated with inhibition of ovulation
 Oral
 Injectable
Highly effective methods that are user independenta
Implantable progestogen only horm onal contraception associated with inhibition of ovulation
 Intrauterine device (IUD)
 Intrauterine hormone -releasing system (IUS)
 Bilateral tubal occlusion
Vasectomized partner 
A vasectomized partner is a highly effective contraception method provided tha t the partner is the sole male sexual partner of the 
WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be 
used.
Sexual abstinence 
Sexual abstinence is considered a highly effective me thod only if defined as refraining from heterosexual intercourse during the 
entire period of risk associated with the study intervention. The reliability of sexual abstinence needs to be evaluated in r elation to 
the duration of the study and the preferred and usual lifestyle of the participant.
NOTES: 
aTypi[INVESTIGATOR_35818]. Use should be consistent with local reg ulations 
regarding the use of contraceptive methods for participants participating in clinical studies. 
PREGNANCY TESTING:
WOCBP should only  be included after a confirmed menstrual period and a negative highly  
sensitive serum pregnancy  test (at Screening). Urine pregnancy  tests will be performed for 
subsequent visits
Additional pregn ancy  testing as shown in the SoA ( Section 1.3) and as follows.
Pregnancy  testing will be performed whenever a menstrual cy cle is missed or when 
pregnancy  is otherwise suspected 
COLLECTION OF PREGNANCY INFORMATION: 
Female participants who become pregnant 
The Investigator will collect pregnancy  information on any  female participant who 
becomes pregnant while participating in this study. I nformation will be recorded on the 
appropriate form and submitted to the Sponsor within 
24 hours of learning of a 
participant's pregnancy . The participant will be followed to determine the outcome of the 
pregnancy . The Investigator will collect follow -up information on the participant and the 
neonate and the in formation will be forwarded to the Sponsor. Generall y, follow -up will 
not be required for longer than 6 to 8 weeks bey ond the estimated delivery date. Any  
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 81termination of pregnancy will be reported, regardless of fetal status (presence or absence 
of anomali es) or indication for the procedure.
Any pregnancy  complication or elective termination of a pregnancy  will be reported as an 
AE or SAE. A spontaneous abortion is always considered to be an SAE and will be 
reported as such. An y post -study  pregnancy  related SAE considered reasonably  related to 
the study  intervention by  [CONTACT_941] I nvestigator will be reported to the Sponsor as described in 
Section 8.3.5. While the Investigator is not obligated to active ly seek this information in 
former stud y participants, he or she may learn of an SAE through spontaneous reporting. 
Any female participant who becomes pregnant while participating in the study  will 
discontinue study  intervention .
10.5 APPENDIX 5: GENETICS
Thepurpose of the pharmacogenomic anal yses is to identify  genomic associations with clinical or 
biomarker response to drug, other COPD clinical outcome measures and possible AEs.   In 
addition, associations between genomic variants and prognosis or progressio n of COPD as well 
asrelated allergic/atopic diseases may  also be studied. These data may  be used or combined with 
data collected from other studies to identify  and validate genomic markers related to the study  
drug or COPD and related diseases.
Analy ses may include sequence determination or single nucleotide pol ymorphism studies of 
candidate genes and surrounding genomic regions.   Other methods, including whole -exome 
sequencing, whole -genome sequencing, DNA copy  number variation, and transcriptome 
sequenc ing (or other methods for quantitating RNA expression) may  also be performed.   The list 
of methods may  be expanded to include novel methodology  that may  be developed during the 
course of this stud y or sample storage period.   Results from the genomic analy ses will not be 
reported in the CSR.
(electronic  
  
1.0)VV-CLIN-0646876 1.0
VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: [ADDRESS_972895] 1 of the criteria in the general guidelines for reporting adverse events in Section 10.3
is met.
10.7 APPENDIX 7: LIST OF PROHIBITED LIVE A TTENUA TED VA CCINES 
Bacillus Calmette -Guérin (BCG) antituberculosis vaccine
Chickenpox (Varicella)
Intran asal influenza (FluMist -Influenza); inactive influenza vaccine delivered by  [CONTACT_125497]
Measles (Rubeola)
Measles -mumps- rubella (MMR) combination
Measles -mumps- rubella -varicella (MMRV) combination
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 84Mumps
Oral polio (Sabin)
Oral ty phoid
Rotavirus
Rubella
Smallpox (Vaccinia)
Varicella Zoster (shingles)
Yellow fever
This list is indicative and not exhaustive
10.8 APPENDIX 8: COUNTRY -SPECIFIC REQUIREMENT S
Not applicable .
10.9 APPENDIX 9: A BBREVIATIONS
ADA: antidrug antibody
AE: adverse event
AECOPD: acute exacerbation of chronic obstructive pulmonary  disease
AESI : adverse event of special interest
CAT: COPD assessment test
COPD: chronic obstructive pulmonary  disease
CRSwNP: chronic rhinosinusitis with nasal poly posis
DMC: data mon itoring committee
DPI: [INVESTIGATOR_714369]: end of treatment
ERS: Evaluating Respi[INVESTIGATOR_714370]: early treatment discontinuation
EXACT: Exacerbations of Chronic Pulmonary  Disease Tool
FEF: forced expi[INVESTIGATOR_714371]: fractional exhaled nitric oxide
FVC: forced vital capacity
ICS: inhaled corticosteroid
IL-4: interleukin 4
IMP: investigational medicinal product
ITT: intent -to-treat
LABA: long acting beta agonist
LAMA: long acting muscarinic antagonist
MDI : metered dose i nhaler
MMRM: mixed -effect model with repeated measures
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 85NIMP: noninvestigational medicinal product
PARC: pulmonary  and activation -regulated chemokine
SABA: short -acting β agonists
SGRQ: St. George's Respi[INVESTIGATOR_714372]: schedule of activities
TEAE : treatment emergent adverse event
(electronic  
  
1.0)VV-CLIN-0646876 1.0
VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 87
(electronic  
 1.0)
VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 88
(electronic  
 1.0)
VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 89
(electronic  
 1.0)
VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 90
(electronic  
 1.0)
VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 91
(electronic  
 1.0)
VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 9210.11 APPENDIX 11: THE EXA CT AS FORMA TTED FOR PERSONA LDIGITA L ASSISTA NT 
(PDA )
(electronic  
 1.0)
VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 93
(electronic  
 1.0)
VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 9410.12 APPENDIX 12: EXA CT Q UESTIONNA IRE
(electronic  
 1.0)
VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 95
(electronic  
 1.0)
VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 96
(electronic  
 1.0)
VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 97
(electronic  
 1.0)
VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 98
(electronic  
 1.0)
VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 99
(electronic  
 1.0)
VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page [ZIP_CODE].13 APPENDIX 13: BODE
(electronic  
  
1.0)VV-CLIN-0646876 1.0
VV-CLIN-0646876 1.0
VV-CLIN-0646876 1.0
VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page [ZIP_CODE].15 APPENDIX 15: DEFINIT ION OF A NAPHYL AXIS
“Anaph ylaxis is a serious allergic reaction that is rapid in onset and may  cause death."
(Adapted from Sampson HA, Munoz -Furlong A, Campbell RL, Adkinson NF, Bock SA , Branum A, et al.  Second 
symposium on the definition and management of anaphylaxis: Summary report —Second National Institute of Allergy 
and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol  2006; 117: 391 -
397)
Clinical criteria for diagnosing anaphylaxis
10.16 APPENDIX 16: LIST OF OPPORTUNISTIC INFECT IONS
Aspergillosis
Blastomy ces dermatitidis (endemic in the south -eastern and south -central states US, along 
Mississippi [INVESTIGATOR_208502])
Candidiasis – only systemic or extensive mucosal or cutaneous candidiasis 
Coccidioides immitis (endemic south -western US and Central and South America)
Cryptococcus
Cytomegalovirus
Herpes Simplex ( disseminated)
Herpes Zoster (disseminated; ophthalmic ; involvement of 2 or more dermatomes)
Histoplasmosis (pulmonary  or disseminated; most common tropi[INVESTIGATOR_260115]-
Ohio- Mississippi [INVESTIGATOR_208504])
Listeriosis
Mycobacterium tuberculosis
Mycobacterium avium
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page 105Nontuberculosis my cobacteria
Pneumocy stis pneumonia (PCP)
This list is indicative and not exhaustive.
10.17 APPENDIX 17: FUTURE USE OF SA MPLES
Not all of the samples collected during this study  may  be required for the tests planned in this 
clinical trial. For patient(s) who have consented to it, the samples that are archived, unused or left 
over after planned testing may  be used for additional research purposes (any genetic analy sis 
subject to additional consent per Section 8.7). For patients who have consented to it, archival 
blood samples will be collected at the visits specified in the study  flow chart (see 
Section 1.3).
Additional details will be provided in the laboratory manual.
These archived serum and plasma samples, and any residual or leftover serum, plasma or blood 
remaining from planned laboratory  work, may  be used for research purposes related to COPD or 
other respi[INVESTIGATOR_714373] (eg, exploratory  biomarkers of 
disease or drug effect), pathway  biology , additional drug safet y assessments or development and 
validation of bioassay  methods bey ond those defined in the pres ent protocol. These samples will 
remain labelled with the same identifiers as the ones used during the stud y (ie, Subject ID, sample 
ID). They  will be transferred to a [COMPANY_011] site (or a subcontractor site) which can be located outside 
of the country  where 
the study  is conducted. The Sponsor has included safeguards for protecting 
subject confidentiality  and personal data ( Section 10.1.3).
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page [ZIP_CODE] REFERENCES
1.Global strategy  for the diagnosis, management, and prevention of chron ic obstructive 
pulmonary  disease (2017 report).
2.Anthonisen NR, Connett JE, Kiley  JP, Altose MD, Bailey  WC, Buist AS, et al.  Effects of 
smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of 
decline of FEV1. The Lung He alth Study .  JAMA. 1994 Nov 16;272(19):[ADDRESS_972896], absent in many. Nat Rev Immunol. 
2015 Jan;15(1):57 -65.
4.Dunican EM, Fah y JV. The Role of Ty pe 2 Inflammation in the Pathogenesis of Asthma 
Exacerbations. Ann Am Thorac Soc. 2015 Nov;[ADDRESS_972897] 2:S144
-9.
5. Ghebre MA, Pang PH, Diver S, Desai D, Bafadhel M, Haldar K, et al. Biological exacerbation 
clusters demonstrate asthma and chronic obstructive pulmonary  disease overlap with distinct 
mediator and microbiome pr ofiles. J Allergy  Clin Immunol. 2018 Jun;141(6):2027 -2036.e12. 
6. Bafadhel M, Saha S, Siva R, McCormick M, Monteiro W, Rugman P, et al. Sputum IL-5 
concentration is associated with a sputum eosinophilia and attenuated b y corticosteroid 
therap y in COPD. Respir ation. 2009;78(3):256
-62.
7.Singh D, Kolsum U, Brightling CE, L ocantore N, Agusti A, Tal -Singer R. Eosinophilic 
inflammation in COPD: prevalence and clinical characteristics. Eur Respir J. 
2014;44(6):1697 -700.
8.Yun JH, Lamb A, Chase R, Singh D, Parker MM, Safer ali A, et al. Blood eosinophil count 
thresholds and exacerbations in patients with chronic obstructive pulmonary disease. J Allergy  
Clin I mmunol. 2018 Jun;141(6):[ADDRESS_972898] 2;104(40):[ZIP_CODE] -
63.
10.Adeloy e D, Chua S, Lee C, Basquill C, Papana A, Theodoratou E, et al. Global an d regional 
estimates of COPD prevalence: s ystematic review and meta -analysis. J Glob Health. 
2015;5(2):[ZIP_CODE].
11.Guarascio AJ, Ray  SM, Finch CK, Self TH. The clinical and economic burden of chronic 
obstructive pulmonary  disease in the [LOCATION_003]. Clinicoecon Outcomes Res. 2013;5(1):235
-45.
12.Brusselle GG, Bracke K, Lahousse L. Targeted therap y with inhaled corticosteroids in COPD 
according to blood eosinophil counts. L ancet Respir Med. 2015;3(6):416 -
7.
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page [ZIP_CODE].Aaron SD, Vandemheen KL , Fergusson D, Maltais F, Bourbeau J, Goldstein R, et al. 
Tiotropi[INVESTIGATOR_96867], Salmeterol, or Fluticasone -Salmeterol for Treatment 
of Chronic Obstructive Pulmonary
 Disease. Ann Intern Med. 2007;146(8):[ADDRESS_972899] in sy mptomatic chronic obstructive pulmonary  disease: two randomized clinical 
trials. L ancet. 2009;374(9691):685-94.
15. Brusselle, G Pavord ID, Landis S, Pascoe S, Lettis S, Morjaria N, et al. Blood eosinophil 
levels as a biomarker in COPD. 
Resp Med, 2018;138: 21-31.
16.Pavord ID, Chanez P, Criner GJ, Kerstjens HAM, Korn S, L ugogo N, et al. Mepolizumab for 
Eosinophilic Chronic Obstructive Pulmonary  Disease. N Engl J Med. [ADDRESS_972900] 
26;377(17):[ADDRESS_972901] CK, et al. 
Benralizumab for chronic obstructive pulmonary  disease and sputum eosinophilia: a 
randomized, double -blind, placebo -controlled, phase 2a stud y.Lancet Respir Med. 
2014;2(11):891 -901.
18.Bafahdel M, McKenna S, Terry  S, Mistry  V, Reid C, Haldar P, et al. Acute Exacerbations of 
Chronic Obstructive Pulmonary
 Disease. Identification of Biologic Clusters and Their 
Biomarkers. Am J Respir Crit Care Med 2011;184:662-71.
19.Christenson SA, Steiling K, van den Berge M, Hijazi K, Hiemsa PS, P ostma DS, et al. 
Asthma -COPD Overlap. Clinical Relevance of Genomic Signatures of Ty pe 2 Inflammation 
in Chronic Obstructive Pulmonary  Disease. Am J Respir Crit Care Med 2015;191:[ADDRESS_972902] 
Pulmon Dis 2014;9:[ADDRESS_972903]  inflammation in COPD. I nt J COPD 2006;1:39 -
47.
22. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardization 
of spi[INVESTIGATOR_038] . Series ‘‘ATS/ERS TASK FORCE: Standardization of L ung Function Testing"  
Edited by  [CONTACT_714401] o V, Crapo R, and Viegi G. Eur Resir J. 2005 Aug;26(2):[ADDRESS_972904] George's Respi[INVESTIGATOR_21606]. Respir 
Med. 1991 Sep;[ADDRESS_972905] B:25- 31; discussion [ADDRESS_972906]. George's Respi[INVESTIGATOR_21606]. Am Rev Respir 
Dis. 1992 Jun;145(6):1321-7.
(electronic  
  
1.0)VV-CLIN-0646876 1.0
Clinical Trial Protocol
EFC15804 (BOREAS)-dupi[INVESTIGATOR_12458]07-Nov -2018
Version number: 1
Property of the [COMPANY_011] Group -strictly confidential Page [ZIP_CODE].Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, et al. The bod y -
mass index, airflow obs truction, dy spnea, and exercise capacit y index in chronic obstructive 
pulmonary  disease. N Engl J Med. 2004 Mar 4;350(10):1005-12.
(electronic  
  
1.0)VV-CLIN-0646876 1.0
VV-CLIN-0646876 1.0